PA Pulmonary Bootcamp — Respiratory Medicine Syllabus

Domain 1 · Highest PANCE Weight

Obstructive Lung Diseases

Tier 1

Topic 1

Asthma

👁 Free Preview

GINA 2024 · ICS-Formoterol · SABA Paradigm Shift · Exacerbation Management

★★★ PANCE PriorityGINA 2024 Updated

Why the PANCE Tests This

Asthma is the most common chronic lung disease in the US (~8% of adults). Boards test: reversible vs irreversible obstruction, the SABA-alone paradigm shift, LABA monotherapy contraindication, exacerbation management, and the silent chest danger sign.

Core Recognition & Diagnosis

Episodic: Wheeze, chest tightness, cough (especially nocturnal), dyspnea — triggered by allergens, exercise, cold air, irritants
Spirometry: Obstructive pattern (FEV1/FVC <0.70 or below LLN) with reversibility ≥12% AND ≥200 mL improvement in FEV1 after bronchodilator
Normal spirometry ≠ no asthma — if clinical suspicion high, order methacholine challenge (positive = ≥20% decline in FEV1 at ≤4 mg/mL)
Peak flow variability >10% diurnal variation supports diagnosis

GINA 2024 Stepwise Management — The Paradigm Shift

⚑ Major Paradigm Shift — SABA-Only is No Longer Recommended

ALL asthma patients need ICS-containing therapy — even mild/intermittent. SABA-only treatment is no longer recommended at any GINA step.
As-needed ICS-formoterol reduces exacerbations by ≥60% vs SABA alone
LABA monotherapy (without ICS) is CONTRAINDICATED in asthma — increases risk of asthma-related death. LABAs must ALWAYS be combined with ICS.

GINA Step	Severity	Track 1 (Preferred) — ICS-Formoterol	Track 2 (Alternative) — SABA Reliever
Steps 1–2	Mild	As-needed low-dose ICS-formoterol ONLY (no daily controller)	ICS taken whenever SABA used (Step 1); daily low-dose ICS + PRN SABA (Step 2)
Step 3	Moderate	Low-dose ICS-formoterol MART (maintenance AND reliever)	Low-dose ICS-LABA + PRN SABA
Step 4	Moderate-severe	Medium-dose ICS-formoterol MART	Medium-dose ICS-LABA + PRN SABA
Step 5	Severe	High-dose ICS-formoterol MART + add-on: LAMA, biologics (dupilumab, mepolizumab), azithromycin	High-dose ICS-LABA + LAMA + PRN SABA; consider biologics

Acute Exacerbation Management

Severity	Key Features	Treatment
Mild-Moderate	SpO₂ >92%, able to speak sentences	SABA MDI + spacer or nebulizer q20min × 3; oral prednisone 40–50mg × 5 days (no taper ≤7 days); ipratropium for moderate exacerbations
Severe	SpO₂ <92%, unable to speak full sentences, accessory muscle use	Continuous nebulized albuterol + ipratropium; IV methylprednisolone; IV magnesium sulfate 2g IV over 20 min (for severe not responding); O₂ to maintain SpO₂ 93–95%
Life-Threatening	Silent chest, cyanosis, exhaustion, altered consciousness, PaCO₂ rising	Prepare for intubation; all of above; call ICU; allow permissive hypercapnia on mechanical ventilation

⚑ Board Traps — Asthma

Silent chest in acute asthma = impending respiratory failure — no air movement. This is MORE dangerous than audible wheezing, not better.
Normal or rising PaCO₂ in severe asthma = respiratory muscle fatigue and impending arrest — asthmatic patients should be hyperventilating (low PaCO₂). A "normal" PaCO₂ of 40 in a severe exacerbation is a red flag.
Do NOT sedate the agitated asthmatic — agitation = hypoxia, not anxiety. Sedation removes the respiratory drive.
Heliox (helium-oxygen mixture): May be considered for severe refractory exacerbation to reduce airway resistance — reduces work of breathing.
Asthma + NSAID use: ~10% of asthmatics have aspirin/NSAID-exacerbated respiratory disease (AERD/Samter's triad: asthma + nasal polyps + NSAID sensitivity). Avoid NSAIDs.
Cough-variant asthma: Chronic cough only, no wheeze. Spirometry may be normal → methacholine challenge.

★ Memory Trick

SABA-only = NEVER in 2024. "Every asthmatic gets ICS, even mild ones." LABA in asthma: "LABA alone = death risk → always marry it to ICS" Silent chest: "Quiet = Danger. Wheezing = still moving air. Silence = moving NOTHING." PaCO₂ rising in asthma: "Normal CO₂ is ABNORMAL — they should be blowing it off" Mg in severe asthma: "Mag relaxes bronchospasm when nothing else works — 2g IV over 20 min"

Clinical Vignette

A 22-year-old woman with asthma presents with severe dyspnea. On exam: she can only speak 2–3 words at a time, HR 128, RR 34, SpO₂ 88%. Lung exam shows minimal wheezing. ABG: pH 7.38, PaCO₂ 42, PaO₂ 55.

Answer: This is a life-threatening asthma exacerbation. The PaCO₂ of 42 is ABNORMAL — she should be hyperventilating with PaCO₂ in the 30s. "Minimal wheezing" with severe clinical distress = near-silent chest from severe obstruction. Start continuous albuterol + ipratropium nebulization, IV methylprednisolone, IV magnesium 2g, and prepare for intubation. ICU admission.

Rapid Review Bullets

Asthma = reversible obstruction (≥12% + ≥200mL FEV1 improvement post-BD)
GINA preferred reliever: ICS-formoterol (budesonide-formoterol) — even for PRN use
IV Mg 2g: for severe exacerbation not responding to bronchodilators
O₂ target in asthma exacerbation: SpO₂ 93–95% (not 100%)
Biologics for step 5: dupilumab, mepolizumab, benralizumab, omalizumab (if allergic)
Steroid course for exacerbation: 5 days, no taper needed if ≤7 days

Tier 1

Topic 2

Chronic Obstructive Pulmonary Disease (COPD)

👁 Free Preview

GOLD 2026 ABE Groups · Pharmacotherapy · LTOT · BiPAP · Exacerbation

★★★ PANCE PriorityGOLD 2026 Updated

Core Recognition & Diagnosis

Post-bronchodilator FEV1/FVC <0.70 confirms fixed airflow obstruction
Emphysema: Destruction of alveolar walls → air trapping, barrel chest, decreased breath sounds, pursed-lip breathing, hyperinflation on CXR
Chronic bronchitis: Productive cough ≥3 months/year for ≥2 consecutive years. "Blue bloaters" — hypercapnia, cor pulmonale
COPD vs Asthma: COPD = irreversible (or minimally reversible). Asthma = reversible. Key distinction on PANCE.

GOLD 2026 Classification

SPIROMETRIC SEVERITY (GOLD 1-4)

Grade	FEV1 % Predicted
GOLD 1 (Mild)	≥80%
GOLD 2 (Moderate)	50–79%
GOLD 3 (Severe)	30–49%
GOLD 4 (Very Severe)	<30%

ABE GROUPS (2023 UPDATE)

Group	Symptoms	Exacerbations
A	Low (mMRC <2, CAT <10)	0–1/year, no hospitalization
B	High (mMRC ≥2, CAT ≥10)	0–1/year, no hospitalization
E	Any	≥2/year OR ≥1 hospitalization

Groups C and D were merged into Group E in the 2023 GOLD update.

Pharmacotherapy by GOLD Group

Group	Initial Treatment	Escalation	ICS?
A	Single bronchodilator (LAMA or LABA)	Add second bronchodilator	No
B	LAMA + LABA (dual bronchodilator)	Triple therapy if still symptomatic	No (unless eos ≥300)
E	LAMA + LABA	Triple therapy (ICS/LABA/LAMA) if blood eos ≥300 or continued exacerbations	Consider if eos ≥300

Blood eosinophil count guides ICS use in COPD: ≥300 cells/μL = likely benefit from ICS; <100 = unlikely benefit; 100–300 = depends on exacerbation frequency
LABA monotherapy is ACCEPTABLE in COPD (unlike asthma where it is contraindicated alone)
ICS monotherapy is NEVER appropriate in COPD — always combine with long-acting bronchodilator
Roflumilast (PDE4 inhibitor): For severe COPD with chronic bronchitis and frequent exacerbations despite triple therapy

Non-Pharmacologic Management

Smoking cessation: Single most important intervention to slow FEV1 decline. Offer varenicline (first-line), bupropion, or nicotine replacement.
Pulmonary rehabilitation: Improves exercise capacity, dyspnea, and QOL. Recommended for GOLD B and E.
Long-Term Oxygen Therapy (LTOT):

LTOT Indications (Use ≥15 hours/day)

PaO₂ ≤55 mmHg OR SpO₂ ≤88% at rest — primary indication
PaO₂ 55–60 mmHg WITH evidence of: pulmonary hypertension, cor pulmonale, or polycythemia (Hct >55%)
LTOT does NOT benefit moderate hypoxemia (SpO₂ 89–93%) — LOTT trial: no survival or hospitalization benefit
LTOT does NOT benefit exercise-induced desaturation only
O₂ target in COPD: 88–92% — excessive O₂ worsens hypercapnia in CO₂ retainers (suppresses hypoxic drive)

Vaccinations: Influenza (annual), pneumococcal (PCV20), COVID-19, RSV (age ≥60)

COPD Exacerbation Management

Bronchodilators: Increase SABA ± ipratropium frequency
Systemic corticosteroids: Prednisone 40 mg PO × 5 days (no taper) — longer courses show no benefit
Antibiotics: Indicated when ≥2 of: increased dyspnea, increased sputum volume, increased sputum purulence (Anthonisen criteria) — amoxicillin/clavulanate, azithromycin, or doxycycline
NIV (BiPAP): First-line for acute hypercapnic respiratory failure (pH <7.35, PaCO₂ >45) — reduces intubation rate, mortality, and ICU length of stay

⚑ Board Traps — COPD

ICS monotherapy is NEVER appropriate in COPD — always combine with LABA or LAMA
ICS in COPD increases pneumonia risk — use only when clearly indicated
LTOT target SpO₂ is 88–92% — do NOT target 95–100% in CO₂ retainers
LTOT does NOT help moderate hypoxemia (SpO₂ 89–93%) — LOTT trial proved no benefit
BiPAP is first-line for COPD exacerbation with respiratory failure — NOT intubation. Intubate only if BiPAP fails or is contraindicated.
COPD exacerbation antibiotics: Indicated for purulent sputum — unlike asthma where antibiotics are NOT routine
GOLD Groups C and D no longer exist — merged into Group E in 2023 update
Alpha-1 antitrypsin deficiency: Think COPD in a never-smoker <45 with lower lobe-predominant emphysema

★ Memory Trick

COPD O₂ target: "88–92% — not too much, not too little" LTOT: "55 or less = definitely yes. 89–93% only = LOTT trial says NO." BiPAP in COPD: "B for BEFORE intubation — always try BiPAP first" COPD ABE: "A = Any bronchodilator. B = Both LAMA+LABA. E = Exacerbations = consider triple + ICS if eos ≥300" "LABA alone OK in COPD — NOT in asthma" (asthma = LABA needs ICS partner always)

🔒 Full Bootcamp Access

You've seen the preview.
Unlock all 17 Pulmonary topics.

These 2 topics are free — a real look at how we teach. The remaining 15 topics below, along with interactive diagrams, EKG popups, Module D differentials, Module E board pearls, and audio mnemonics, are included with bootcamp enrollment.

Everything in the full Pulmonary syllabus

17 fully-worked clinical topics

Interactive SVG anatomy diagrams

Module D — must-know differentials

Module E — domain board pearls

Animated EKG strips & 12-lead viewer

Audio mnemonics per topic

20 PANCE-style board questions

Clinical vignettes + teaching pearls

🔒 Pulmonary Function Test Interpretation 🔒 Community-Acquired Pneumonia (CAP) 🔒 Tuberculosis (TB) 🔒 Interstitial Lung Disease (ILD) & Idiopath 🔒 Sarcoidosis 🔒 Pulmonary Embolism 🔒 Pulmonary Hypertension & Cor Pulmonale 🔒 Pleural Effusions 🔒 Pneumothorax 🔒 Lung Cancer 🔒 Acute Respiratory Distress Syndrome (ARDS) 🔒 Obstructive Sleep Apnea (OSA) 🔒 Cystic Fibrosis 🔒 Pertussis & Acute Bronchitis + 1 more topics

Enroll in Bootcamp → Learn More

📚5 complete systems

🎯Pre & post-rotation assessment

📟Full EKG library

🩺84 clinical vignettes

👨‍⚕️Dr. Rajiv Choudhary, MD MPH

🔑

Have an access code?

Enter your bootcamp access code to unlock the full syllabus.

❌ Incorrect code — check with your instructor

Don't have a code? Enroll in the bootcamp →

Tier 1

Topic 3

Pulmonary Function Test Interpretation

FEV1/FVC · Obstructive vs Restrictive · TLC · DLCO · Pattern Recognition

★★★ PANCE PriorityRestriction Trap

🔒 Full content available with bootcamp enrollment. Get access →

The 5-Step PFT Approach

Step	Parameter	Finding	Interpretation
1	FEV1/FVC	<0.70 (or below LLN)	Obstructive pattern → go to Step 3
1	FEV1/FVC	Normal (≥0.70)	Not obstructive → go to Step 2
2	FVC	Low with normal FEV1/FVC	Possible restrictive → MUST confirm with TLC
2	FVC	Low with low FEV1/FVC	Possible mixed pattern → confirm TLC
3	Bronchodilator response	≥12% AND ≥200 mL FEV1 ↑	Reversible → suggests asthma
3	Bronchodilator response	Minimal change	Irreversible → suggests COPD
4	TLC (full lung volumes)	<80% predicted	TRUE restrictive pattern confirmed
4	TLC	>120% predicted	Hyperinflation (emphysema, air trapping)
5	DLCO (diffusing capacity)	Low	Emphysema, ILD, pulmonary vascular disease, anemia
5	DLCO	Normal	Asthma, chronic bronchitis (without emphysema)
5	DLCO	High	Pulmonary hemorrhage, polycythemia, L→R shunt, obesity

Pattern Summary — The Most Tested Combinations

Diagnosis	FEV1/FVC	FVC	TLC	DLCO
Asthma	↓	Normal or ↓	Normal or ↑	Normal or ↑
COPD / Emphysema	↓	Normal or ↓	↑ (hyperinflation)	↓
Chronic Bronchitis	↓	Normal or ↓	Normal or ↑	Normal
Restrictive (ILD, obesity)	Normal or ↑	↓	↓	↓ (if ILD)
Neuromuscular (ALS, MG)	Normal	↓ (↓↓ supine)	↓	Normal
Mixed (COPD + ILD)	↓	↓↓	Variable	↓↓

⚑ Board Traps — PFTs

Restrictive disease CANNOT be diagnosed by spirometry alone — a low FVC with normal FEV1/FVC is only SUGGESTIVE of restriction. TLC measurement (full lung volumes) is required to confirm.
DLCO differentiates emphysema (low) from chronic bronchitis (normal) and asthma (normal/high) — the single most useful DLCO question on boards
Fixed ratio of 0.70 overdiagnoses COPD in elderly (normal aging reduces FEV1/FVC) and underdiagnoses in young — LLN is more accurate
Neuromuscular disease: FVC drops significantly from sitting to supine (>25% drop = diaphragm weakness). Normal DLCO helps distinguish from ILD.
Obesity hypoventilation (OHS): Restrictive pattern (low FVC, low TLC), normal DLCO, hypercapnia. BMI >30 + PaCO₂ >45 = OHS.

★ Memory Trick

PFT pattern: "FEV1/FVC low = Obstructive. FEV1/FVC normal + FVC low = Restrictive (confirm with TLC)" "You CANNOT diagnose restriction without TLC — spirometry only suggests it" DLCO: "Emphysema destroys alveoli → destroys gas exchange → DLCO drops. Bronchitis = normal walls = normal DLCO." Reversibility: "12% and 200mL = Asthma switch. Less than that = COPD"

Domain 2 · High PANCE Weight

Infectious Lung Disease

Tier 1

Topic 4

Community-Acquired Pneumonia (CAP)

CURB-65 · PSI · Antibiotic Selection · 3-Day Course Update · Aspiration

★★★ PANCE Priority2024 UpdatedMany Traps

🔒 Full content available with bootcamp enrollment. Get access →

Core Recognition & Severity Scoring

Classic presentation: Fever, productive cough (purulent or rust-colored), pleuritic chest pain, dyspnea, elevated WBC
CXR: Lobar or segmental consolidation. CT is more sensitive if CXR equivocal.

Score	Parameters	Score → Action	Board Key
CURB-65	Confusion, Urea (BUN >19), RR ≥30, BP (SBP <90 or DBP ≤60), Age ≥65	0–1 → Outpatient; 2 → Consider hospitalization; 3–5 → Hospitalize (4–5 → ICU consideration)	Simple, 5-point score
PSI (Pneumonia Severity Index)	20 variables: age, comorbidities, vitals, labs, CXR	Class I–III → Outpatient; Class IV → Consider hospitalization; Class V → Hospitalize	Preferred by ATS/IDSA — identifies more low-risk outpatients. PSI > CURB-65 per guidelines.

Empiric Antibiotic Therapy

Setting	First-Line Treatment	Alternative	Board Key
Outpatient — No Comorbidities	Amoxicillin 1g TID OR doxycycline 100mg BID	Azithromycin ONLY if local pneumococcal resistance <25%	Azithromycin monotherapy NOT recommended in most US regions (resistance >30%)
Outpatient — With Comorbidities	Amoxicillin/clavulanate or cephalosporin (cefpodoxime, cefuroxime) + macrolide or doxycycline	Respiratory fluoroquinolone monotherapy (levofloxacin 750mg or moxifloxacin 400mg)	Fluoroquinolones: only if β-lactam/macrolide cannot be used
Inpatient — Non-Severe	β-lactam (ceftriaxone) + macrolide (azithromycin)	Respiratory fluoroquinolone monotherapy	Combination preferred
Inpatient — Severe/ICU	β-lactam (ceftriaxone or ampicillin/sulbactam) + macrolide or fluoroquinolone	+ anti-MRSA (vancomycin/linezolid) + anti-pseudomonal ONLY if specific risk factors	IV hydrocortisone 200mg/day reduces mortality in severe CAP (CAPE COD trial)

Duration: Minimum 3–5 days guided by clinical stability criteria (afebrile, HR <100, RR <24, SBP ≥90, SpO₂ ≥90%, able to eat, normal mentation). Longer courses NOT superior.

⚑ Board Traps — CAP

Fluoroquinolones are NOT first-line for CAP — reserve for β-lactam/macrolide intolerance (C. diff risk, tendon rupture, QT prolongation, resistance selection)
Azithromycin monotherapy is NOT recommended as empiric outpatient CAP — macrolide resistance in S. pneumoniae exceeds 30% in most US regions
Do NOT add anti-anaerobic coverage (metronidazole, clindamycin) for aspiration pneumonia — associated with 5–6% higher mortality per 2019 ATS/IDSA guidelines
3-day antibiotic course is sufficient if stability criteria met by day 3 — this is a major update from traditional 7–10 day courses
IV steroids (hydrocortisone 200mg/day) reduce mortality in SEVERE CAP — NOT indicated in mild/moderate CAP
Legionella: Think in severe CAP + hyponatremia + diarrhea + hepatic involvement + exposure to water systems. Urinary antigen is the diagnostic test. Treat with fluoroquinolone or azithromycin.

★ Memory Trick

CURB-65: "Confusion + Urea + Resp rate + Blood pressure + 65 years" — 1 point each PSI > CURB-65 per ATS/IDSA — "PSI is more precise for low-risk outpatient identification" Aspiration pneumonia: "No anaerobes needed — stop adding metronidazole, it hurts more than helps" CAP course: "3 days if stable by day 3 — not 10. Stability = afebrile, HR/RR normal, eating, O₂ ok" "FQs are the backup plan, not the opening play" — use β-lactam + macrolide first

Clinical Vignette

A 68-year-old woman with diabetes presents with 3 days of fever, productive cough, and RUQ pain. BP 110/70, HR 108, RR 26, SpO₂ 92%. CXR shows right lower lobe consolidation. BUN 22, Na 128. She takes amoxicillin regularly for UTIs.

Answer: CURB-65 = 3 (BUN >19, RR ≥30 approximately, age ≥65) → hospitalize. The hyponatremia + RUQ pain suggest Legionella — order urine Legionella antigen. Antibiotic: β-lactam (ceftriaxone) + macrolide (azithromycin) covers both typical and atypical (including Legionella). If she deteriorates → ICU + consider steroids. Minimum course = 3–5 days if clinical stability met.

Tier 1

Topic 5 ★ Gap Added

Tuberculosis (TB)

Latent vs Active · RIPE Therapy · TST vs IGRA · Contact Tracing

★★ High YieldGap TopicTesting Traps

🔒 Full content available with bootcamp enrollment. Get access →

Why the PANCE Tests This

TB is tested every exam. Boards focus on: who to screen, TST vs IGRA interpretation, latent vs active distinction, RIPE therapy duration, and isolation precautions. High-yield because of public health implications.

Latent vs Active TB — The Critical Distinction

	Latent TB Infection (LTBI)	Active TB Disease
Symptoms	None — asymptomatic	Cough >3 weeks, night sweats, weight loss, hemoptysis, fever
CXR	Normal or old granulomas/Ghon complex	Upper lobe infiltrate, cavitation, lymphadenopathy
TST/IGRA	Positive (hallmark of LTBI)	Usually positive (but can be false-negative in immunocompromised)
Sputum AFB smear	Negative	Positive in pulmonary active TB
Contagious?	NO — cannot transmit	YES — airborne droplet nuclei. Requires airborne isolation (negative pressure room + N95)
Treatment goal	Prevent progression to active disease	Cure and prevent transmission

Tuberculin Skin Test (TST) — Interpretation

Induration Threshold	Positive If…
≥5 mm	HIV-positive; recent TB contact; organ transplant / immunosuppressed; CXR with old TB changes
≥10 mm	High-risk occupations (healthcare workers, corrections, homeless); recent immigrants from high-prevalence countries; IV drug users; children <4 years; silicosis, DM, renal failure, malignancy
≥15 mm	Any person with no known risk factors

IGRA (QuantiFERON-TB Gold / T-SPOT.TB): Blood test — preferred over TST when BCG vaccination history is present (BCG does NOT cause false-positive IGRA, but DOES cause false-positive TST)
Preferred LTBI screening test: IGRA for adults >5 years in the US (especially BCG-vaccinated immigrants)

Treatment

Active TB — RIPE Therapy

Rifampin + Isoniazid + Pyrazinamide + Ethambutol × 2 months (intensive phase)
Then Rifampin + Isoniazid × 4 months (continuation phase) = total 6 months
Drug-resistant TB (MDR-TB): Requires specialist consultation, 18–24 months, injectable agents

Latent TB — Treatment Options

Isoniazid (INH) × 9 months — traditional first-line (9H)
Isoniazid + Rifapentine × 3 months (weekly doses) — 3HP, preferred in most patients (high completion rate)
Rifampin × 4 months — alternative if INH contraindicated
Always give Pyridoxine (B6) with INH — prevents peripheral neuropathy

⚑ Board Traps — TB

BCG vaccination causes false-positive TST but NOT IGRA — use IGRA in BCG-vaccinated patients
Airborne isolation (negative pressure room + N95) required for suspected active pulmonary TB — NOT standard droplet precautions
INH toxicity: hepatotoxicity (#1) and peripheral neuropathy — always give pyridoxine (B6) with INH
Rifampin drug interactions: CYP450 inducer — reduces efficacy of warfarin, oral contraceptives, antiretrovirals. Causes orange discoloration of urine/secretions (benign, warn patients).
Ethambutol toxicity: optic neuritis — monitor visual acuity and color vision monthly
Pyrazinamide toxicity: hyperuricemia — can precipitate gout
Miliary TB: Hematogenous dissemination → diffuse bilateral "millet seed" nodules on CXR. Can cause meningitis, bone/joint infection, choroidal tubercles (ophthalmologic exam).

★ Memory Trick

Active TB treatment: "RIPE for 2 months, then RI for 4 months" = 6 months total Drug toxicities: "Rifampin = Red urine (benign). INH = Neuro (give B6) + Liver. Ethambutol = Eyes. Pyrazinamide = gout (uric acid)" TST thresholds: "5 for HIV/contacts/immunosuppressed. 10 for high-risk groups. 15 for everyone else." BCG trap: "BCG fools the TST but NOT the IGRA — use IGRA in immigrants" LTBI modern: "3HP (INH + Rifapentine weekly × 12 doses) = fastest, best adherence"

Domain 3 · Important & Gap Topics

Interstitial & Parenchymal Lung Disease

Tier 2

Topic 6 ★ Gap Added

Interstitial Lung Disease (ILD) & Idiopathic Pulmonary Fibrosis

Honeycombing · Restrictive Pattern · Antifibrotics · Velcro Crackles

★★ High YieldGap Topic

🔒 Full content available with bootcamp enrollment. Get access →

Core Recognition

ILD = diffuse parenchymal lung diseases — heterogeneous group causing progressive fibrosis and/or inflammation
Classic presentation: Progressive exertional dyspnea + dry, non-productive cough + "Velcro" bibasilar crackles (coarse, late-inspiratory) + finger clubbing (in IPF)
PFTs: Restrictive pattern (↓FVC, ↓TLC, normal FEV1/FVC) + low DLCO (most sensitive early finding)

ILD — PANCE Classification

PANCE tests pattern recognition and initial management — not sub-typing of ILD patterns:

ILD Type	Key Features	Treatment
IPF (UIP pattern)	Bilateral basilar honeycombing, traction bronchiectasis on HRCT. Older male smoker. Progressive.	Nintedanib or pirfenidone. NO steroids (worsen IPF).
Hypersensitivity Pneumonitis	Antigen exposure (birds, mold, farmer's lung). Upper/mid lung. Reversible if antigen removed early.	Remove antigen. Steroids for acute severe.
Sarcoidosis (pulmonary)	Bilateral hilar adenopathy. Young Black woman. May be asymptomatic.	Steroids if symptomatic or vital organ involved.
Drug-induced ILD	Amiodarone, methotrexate, nitrofurantoin, bleomycin. History + exposure = key.	Stop offending drug. Steroids if severe.
CTD-associated ILD	RA, SLE, SSc. ILD may precede arthritis symptoms.	Treat underlying CTD + specialist referral.

🩺 PANCE Pearl: IPF is the most tested ILD. The anti-fibrotic rule (nintedanib/pirfenidone) and the no-steroids rule are the two most tested facts.

IPF Treatment

Antifibrotic agents (slow progression): Nintedanib or Pirfenidone — slow FVC decline, do NOT reverse fibrosis
Supplemental oxygen if resting or exertional hypoxemia
Lung transplantation: Definitive treatment for eligible patients
Pulmonary rehabilitation
Corticosteroids are NOT beneficial in IPF — no evidence of benefit; may worsen by increasing infection risk

Diagnostic Approach

HRCT (High-Resolution CT): First-line imaging — shows typical patterns (UIP pattern in IPF: honeycombing, traction bronchiectasis, basal/subpleural predominance)
BAL (Bronchoalveolar Lavage): Rules out infection; lymphocytosis suggests HP or sarcoidosis
Surgical lung biopsy: Gold standard when HRCT is non-diagnostic; often avoided in elderly or frail patients

⚑ Board Traps — ILD

Low DLCO is the most sensitive early finding in ILD — may be abnormal before spirometry shows restriction
Honeycombing + subpleural basal distribution on HRCT = UIP pattern = IPF diagnosis — biopsy not needed if HRCT is typical
Corticosteroids do NOT help IPF — may benefit HP or CTD-ILD but not IPF
Asbestosis vs. Silicosis location: Asbestosis = LOWER lobes. Silicosis = UPPER lobes. Opposite of what you might expect.
Amiodarone toxicity: Bilateral interstitial infiltrates, phospholipidosis on biopsy. Treat by stopping amiodarone; steroids if severe.

Tier 2

Topic 7 ★ Gap Added

Sarcoidosis

Löfgren Syndrome · Bilateral Hilar Adenopathy · Non-Caseating Granulomas · ACE Level

★★ High YieldGap Topic

🔒 Full content available with bootcamp enrollment. Get access →

Core Recognition Pattern

Demographics: African American women aged 20–40 most commonly. Also Scandinavian. Winter/spring clustering.
Classic presentation: Bilateral hilar lymphadenopathy (BHL) on CXR ± constitutional symptoms (fatigue, weight loss, fever)
Pulmonary: Dyspnea, dry cough. Upper/mid lobe predominance on imaging.
Labs: Elevated ACE level (50–80% sensitive), elevated calcium (hypercalciuria even if serum Ca2+ normal), elevated alkaline phosphatase

Systemic Manifestations — The Classic Boards Associations

System	Manifestation	Board Key
Skin	Erythema nodosum (tender red nodules on shins), Lupus pernio (violaceous facial plaques)	Erythema nodosum in sarcoid = good prognosis
Eyes	Anterior uveitis (most common), posterior uveitis, optic neuritis	Screen all sarcoid patients with slit-lamp exam
Heart	Cardiac sarcoid: Complete heart block, VT, sudden death	Most common cause of death from cardiac sarcoid = arrhythmia. Holter monitor + cardiac MRI.
Nervous system	Facial nerve palsy (CN VII most common), meningitis, hypothalamic dysfunction	Neurosarcoid = poor prognosis; treat aggressively
Kidney	Hypercalciuria → nephrolithiasis, nephrocalcinosis	Mechanism: granulomas produce excess 1,25-VitD
Löfgren Syndrome	BHL + erythema nodosum + ankle periarthritis (± fever)	EXCELLENT prognosis — spontaneous resolution in 85–90%. May not need steroids.

Diagnosis & Treatment

Gold standard: Biopsy showing non-caseating granulomas with exclusion of other causes (TB, fungal infection). Safest biopsy site: skin, peripheral lymph nodes, or endobronchial (EBUS-TBNA).
Löfgren syndrome: Clinical diagnosis — biopsy NOT required in classic presentation
First-line treatment: Oral corticosteroids (prednisone 20–40 mg/day) — for symptomatic pulmonary disease, cardiac, ocular, neurologic, or hypercalcemia
Steroid-sparing agents: Methotrexate, azathioprine, hydroxychloroquine (mild disease)

⚑ Board Traps — Sarcoidosis

Non-caseating granulomas = sarcoidosis. Caseating granulomas = TB — key histologic distinction
ACE level is NOT diagnostic — elevated in only 50–80%, and can be elevated in other granulomatous diseases
Löfgren syndrome = NO biopsy needed — classic clinical presentation is sufficient for diagnosis
Sarcoid hypercalcemia: Granulomas produce excess calcitriol (1,25-VitD) → hypercalciuria even with normal serum Ca2+. Avoid high-calcium diet and sunlight exposure.
Cardiac sarcoidosis: AV block in a young patient without obvious structural disease = think cardiac sarcoid. Confirmed with cardiac MRI (LGE) or FDG-PET.

★ Memory Trick

Sarcoid classic: "BHL + young Black woman + elevated ACE + non-caseating granulomas" Löfgren: "BHL + erythema nodosum + ankle arthritis = Löfgren = Lucky prognosis (self-resolves)" Granuloma distinction: "Non-caseating = Sarcoid. Caseating = TB." (Caseating = cheese-like = TB "caseation") Calcium: "Granulomas make vitamin D → calcium goes up → kidneys spill it → stones" Cardiac sarcoid: "Young person with heart block + no obvious cause = think sarcoid"

Domain 4 · High Yield

Pulmonary Vascular Disease

Tier 1

Topic 8

Pulmonary Embolism

Wells · PERC · CTPA · Massive vs Submassive · DOACs · 2026 AHA/ACC Guidelines

★★★ PANCE Priority2026 GuidelinesMany Traps

🔒 Full content available with bootcamp enrollment. Get access →

Core Recognition & Diagnostic Algorithm

Classic triad: Dyspnea + pleuritic chest pain + hemoptysis (present in <20% of cases — classic but rare)
Most common symptom: Dyspnea alone
EKG findings: Sinus tachycardia (#1), S1Q3T3 (classic but insensitive), new RBBB, T-wave inversions V1–V4
Massive PE: Sudden hemodynamic collapse, RV strain on echo, troponin and BNP elevation

Stepwise Diagnostic Approach

Wells Score + PERC + D-Dimer Algorithm

Step 1: Calculate Wells score. Score ≤4 = PE unlikely → proceed to PERC or D-dimer. Score >4 = PE likely → CTPA directly.
PERC rule: If low pretest probability (<15%) AND all 8 criteria met → PE excluded without D-dimer (age <50, HR <100, SpO₂ >94%, no prior VTE, no surgery/trauma, no hemoptysis, no unilateral leg swelling, no estrogen use)
D-dimer: For low/intermediate probability. If negative (<500 ng/mL or age-adjusted: age × 10 for age >50) → PE excluded. If positive → CTPA.
CTPA: Gold standard imaging — sensitivity ~98%, specificity ~97%.
V/Q scan: Alternative if CTPA contraindicated (contrast allergy, renal insufficiency, pregnancy)

Risk Stratification & Treatment

Category	Definition	Mortality	Treatment
Massive PE (High-risk)	SBP <90 mmHg or vasopressor requirement or cardiac arrest	~5–58%	Systemic thrombolysis (alteplase 100mg IV over 2h) + anticoagulation. Surgical embolectomy or catheter-directed therapy if lytics contraindicated.
Submassive (Intermediate)	Hemodynamically stable + RV dysfunction on echo/CT AND/OR elevated troponin or BNP	~3–15%	Anticoagulation alone. Consider catheter-directed thrombolysis (CDT) or systemic lytics ONLY if hemodynamic deterioration occurs.
Low-risk PE	Hemodynamically stable, no RV dysfunction, normal biomarkers (PESI Class I–II)	<1%	DOACs. Consider outpatient treatment if PESI low-risk, no contraindications, and reliable follow-up.

Anticoagulation Selection

Agent	Parenteral Bridge?	Key Notes
Apixaban (preferred)	NO	10mg BID × 7d, then 5mg BID. Most commonly used DOAC for PE.
Rivaroxaban	NO	15mg BID × 21d, then 20mg daily.
Dabigatran	YES — 5–10 days LMWH first	Then dabigatran PO. Cannot use without parenteral lead-in.
Edoxaban	YES — 5–10 days LMWH first	Then edoxaban PO.
Warfarin	YES — heparin bridge until INR ≥2	Second-line. First-line for: antiphospholipid syndrome, mechanical valves.
LMWH	—	Preferred for cancer-associated VTE (though DOACs now acceptable for most cancer patients without GI/GU malignancy)

Duration of Anticoagulation

Provoked PE (reversible major risk factor — surgery, trauma, immobility): 3 months, then stop
Unprovoked PE: Extended (indefinite) anticoagulation — reduced-dose apixaban 2.5mg BID or rivaroxaban 10mg daily after initial 6 months
Cancer-associated PE: Continue as long as cancer active
First unprovoked + high bleeding risk: 3–6 months then reassess — shared decision-making

⚑ Board Traps — PE

DOACs are first-line for PE treatment — warfarin is no longer preferred (except antiphospholipid syndrome)
DOACs are absolutely contraindicated in antiphospholipid syndrome — use warfarin (TRAPS trial: DOACs inferior)
Thrombolysis for MASSIVE PE only (SBP <90) — NOT for submassive PE unless hemodynamic deterioration
IVC filter: ONLY if anticoagulation absolutely contraindicated — NOT as routine adjunct to anticoagulation
D-dimer is a RULE-OUT test ONLY — do NOT order in high-probability patients (go straight to CTPA). Positive D-dimer does NOT diagnose PE.
PERC only applies to LOW pre-test probability (<15%) — never apply to moderate or high-risk patients
Subsegmental PE in low-risk patients without DVT: May observe without anticoagulation — evolving evidence
Apixaban and rivaroxaban require NO initial parenteral anticoagulation — dabigatran and edoxaban DO require 5–10 days of LMWH first

★ Memory Trick

Wells ≤4 + PERC negative = NO PE (no imaging needed) Wells ≤4 + PERC positive = D-dimer Wells >4 = CTPA directly (skip D-dimer) DOACs: "Apixaban and Rivaroxaban = No bridge needed. Dabigatran and Edoxaban = Need 5-10 days LMWH first." Thrombolysis: "Massive PE (SBP <90) = lyse. Submassive = wait. Low-risk = DOAC and go home." APS: "Antiphospholipid syndrome = Warfarin ONLY. DOACs fail in APS."

Clinical Vignette

A 35-year-old woman on oral contraceptives presents with 3 days of right pleuritic chest pain and dyspnea. HR 105, SpO₂ 94%, RR 20. Wells score = 5 (HR >100 + PE most likely dx). Echo shows RV dilation. Troponin is elevated. CTPA confirms bilateral PE. BP is 118/76.

Answer: Submassive (intermediate-risk) PE — hemodynamically stable but RV dysfunction + elevated troponin. Start anticoagulation immediately (apixaban 10mg BID × 7 days — no bridge needed). Do NOT give systemic thrombolytics unless BP drops below 90. Admit for monitoring. If she deteriorates hemodynamically → consider catheter-directed therapy or systemic lytics. Anticoagulate for at least 3 months (OCP is a provoked risk factor — stop OCP); consider extended therapy given her age and continued OCP risk if it would be resumed.

Tier 2

Topic 9 ★ Gap Added

Pulmonary Hypertension & Cor Pulmonale

WHO Groups · RHC Diagnosis · Vasodilators · Cor Pulmonale Management

★★ High YieldGap Topic

🔒 Full content available with bootcamp enrollment. Get access →

Core Recognition

Definition: Mean pulmonary artery pressure (mPAP) ≥20 mmHg at rest on right heart catheterization (RHC)
Classic presentation: Progressive exertional dyspnea (most common) → syncope → right heart failure (JVD, hepatomegaly, peripheral edema, ascites)
Signs: Loud P2 (pulmonic component), right-sided S3/S4, parasternal heave, TR murmur
EKG: Right axis deviation, RVH (R wave dominant in V1), P pulmonale (peaked P waves in II)
Echo (screening): Elevated RV systolic pressure, RV dilation/hypertrophy, flattening of interventricular septum ("D-shaped" LV). Definitive diagnosis = RHC.

WHO Classification — 5 Groups

Group	Mechanism	Common Causes	Treatment Approach
Group 1 — PAH	Arterial/pre-capillary	Idiopathic, heritable, connective tissue disease (SSc), HIV, portal HTN, drugs (cocaine, meth, anorexigens)	Targeted PAH therapy (see below)
Group 2 — Left heart disease	Post-capillary (elevated PCWP)	HFpEF, HFrEF, valvular disease	Treat underlying heart disease — PAH-specific drugs NOT indicated
Group 3 — Lung disease	Hypoxia-driven	COPD, ILD, OSA, hypoxia	Treat underlying lung disease, supplemental O₂
Group 4 — CTEPH	Chronic thromboembolic obstruction	Unresolved PE → organized thrombus	Pulmonary endarterectomy (curative if accessible) or riociguat
Group 5 — Multifactorial	Unclear/multifactorial	Sarcoid, sickle cell, metabolic disorders	Treat underlying cause

PAH-Specific Treatment (Group 1 Only)

Endothelin receptor antagonists (ERAs): Ambrisentan, bosentan, macitentan — vasodilators + antiproliferative
PDE5 inhibitors: Sildenafil, tadalafil — vasodilators. Note: contraindicated with nitrates (severe hypotension)
Prostacyclin analogs: Epoprostenol (IV, most potent, continuous infusion), treprostinil, iloprost (inhaled)
sGC stimulator: Riociguat — also used for CTEPH (Group 4)
Vasoreactivity testing (nitric oxide challenge): ~10% of Group 1 patients respond → treat with CCBs (amlodipine, nifedipine, diltiazem). Only these patients benefit from CCBs.

Cor Pulmonale

Definition: Right ventricular hypertrophy and/or failure due to pulmonary hypertension from lung disease (Group 3)
Most common cause: COPD
Signs: JVD, peripheral edema, hepatomegaly, parasternal heave, loud P2
Management: Treat underlying lung disease, LTOT (if hypoxemic), diuretics for volume overload, anticoagulation if PE suspected
Avoid vasodilators (nitrates, CCBs) in cor pulmonale without proper testing — can cause systemic hypotension and worsen RV perfusion

⚑ Board Traps — Pulmonary HTN

Definitive diagnosis requires right heart catheterization (RHC) — echo is screening only
PAH-specific drugs (ERAs, PDE5i, prostacyclins) are ONLY for Group 1 PAH — NOT for Group 2 (left heart) or Group 3 (lung disease)
Group 2 (HF-related PH): PAH drugs may be HARMFUL — can worsen pulmonary edema by increasing pulmonary blood flow into a failing left heart
CTEPH is potentially curable with pulmonary endarterectomy — don't miss this diagnosis in patients with prior PE and persistent PH
Sildenafil + nitrates = absolute contraindication (both cause vasodilation → profound hypotension)

Domain 5 · High Yield

Pleural Disease

Tier 1

Topic 10

Pleural Effusions

Light's Criteria · Transudate vs Exudate · Parapneumonic · Empyema · pH <7.2

★★★ PANCE PriorityLight's Trap

🔒 Full content available with bootcamp enrollment. Get access →

Light's Criteria — Exudate if ANY ONE Met

Light's Criteria (All 3 Together — Exudate if ANY one positive)

Pleural fluid protein / Serum protein >0.5
Pleural fluid LDH / Serum LDH >0.6
Pleural fluid LDH >2/3 the upper limit of normal serum LDH
Sensitivity ~98%, Specificity ~72% — misclassifies ~25% of transudates as exudates (especially diuretic-treated HF)

Common Causes

Transudate (SAAG ≥1.2, or Light's negative)	Exudate (Light's positive)
Heart failure (#1 overall cause)	Parapneumonic / Empyema (#1 exudative)
Cirrhosis (hepatic hydrothorax)	Malignancy (#2 exudative)
Nephrotic syndrome	Pulmonary embolism (can be either)
Hypothyroidism	TB pleuritis (lymphocytic exudate)
	Autoimmune (RA — very low glucose; SLE)

Parapneumonic Effusions — The pH <7.2 Rule

Type	Fluid Characteristics	Treatment
Simple parapneumonic	pH >7.2, glucose >60, LDH <1000, cultures negative	Antibiotics alone — will resolve
Complicated parapneumonic	pH ≤7.2, glucose ≤60, LDH >1000, OR positive culture/Gram stain	Antibiotics + chest tube drainage (MANDATORY)
Empyema	Frank pus in pleural space	Antibiotics + chest tube drainage. If loculated → fibrinolytics instilled intrapleurally or VATS decortication.

Additional Diagnostic Tests

Pleural fluid pH: Most important single test for complicated parapneumonic — pH ≤7.2 = drain
Glucose: Very low (<30) = RA (rheumatoid arthritis) or empyema. RA is the lowest.
Triglycerides >110: Chylothorax (thoracic duct injury) — creamy white milky appearance
Hematocrit >50% of serum Hct: Hemothorax — requires chest tube
Elevated amylase: Pancreatitis, esophageal rupture (Boerhaave)
Pleural fluid ADA >40: TB pleuritis (in appropriate geographic/clinical context)

⚑ Board Traps — Pleural Effusions

Light's criteria can misclassify HF effusions as exudates in diuretic-treated patients — if HF is the suspected cause but Light's says exudate → check serum-to-pleural albumin gradient (>1.2 g/dL = transudate)
NT-proBNP >1500 pg/mL in pleural fluid = HF etiology confirmed (even if Light's says exudate)
Pleural fluid pH ≤7.2 = complicated parapneumonic → chest tube (mandatory) — the single most important decision point in parapneumonic effusions
RA effusion has the lowest pleural glucose (often <30 mg/dL, sometimes near 0) — classic board fact
Bilateral effusions + HF → treat with diuretics first, thoracentesis not initially required. Unilateral or atypical → always tap.

★ Memory Trick

Light's criteria: "An effusion is Exudative if ANY one of three ratios is met" "Protein >0.5, LDH ratio >0.6, LDH >2/3 ULN — any one = exudate" Parapneumonic pH: "pH 7.2 or less = Drain. pH above 7.2 = treat with ABx alone" "RA effusion has the lowest glucose of any effusion — it's the most hostile environment" HF Light's trap: "HF on diuretics → Light's may lie → check albumin gradient (>1.2 = transudate)"

Tier 1

Topic 11

Pneumothorax

Primary vs Secondary · Tension PTX · Needle Decompression · Chest Tube · Recurrence

★★★ PANCE PriorityClinical Diagnosis Trap

🔒 Full content available with bootcamp enrollment. Get access →

Core Recognition

Type	Classic Patient	Key Feature	Management
Primary Spontaneous	Tall, thin young male, no lung disease	Rupture of apical blebs. Sudden pleuritic pain + dyspnea. Well-tolerated.	Small (<2cm): observation + O₂. Large/symptomatic: needle aspiration or small-bore chest tube.
Secondary Spontaneous	COPD, ILD, PCP — underlying lung disease	Poorly tolerated — limited pulmonary reserve. Higher morbidity.	Lower threshold for chest tube. Do NOT observe — these patients decompensate.
Traumatic	Post-trauma (MVA, rib fractures, penetrating)	May have hemothorax (hemopneumothorax)	Chest tube (large-bore for hemopneumothorax)
Iatrogenic	Post-central line, thoracentesis, ventilator	May be small if procedure-related	Chest tube if on positive pressure ventilation (mandatory)
Tension	Any — trauma, mechanical ventilation	Mediastinal shift AWAY from PTX, tracheal deviation, JVD, hypotension, absent breath sounds	IMMEDIATE needle decompression (14-16G, 2nd ICS, MCL) then chest tube. DO NOT wait for CXR.

Tension Pneumothorax — The Emergency

⚑ Tension PTX = Clinical Diagnosis — DO NOT Wait for CXR

Mechanism: One-way valve — air enters pleural space on inspiration but cannot escape → progressive pressure → mediastinal shift → kinks great vessels → circulatory collapse
Classic triad: Absent breath sounds unilaterally + tracheal deviation AWAY from affected side + hypotension
Immediate treatment: Needle decompression — 14–16 gauge needle, 2nd intercostal space, midclavicular line (or 4th/5th ICS anterior axillary line in obese) → immediately followed by chest tube
On mechanical ventilation: Sudden ↑ peak airway pressures + ↓ O₂ saturation + hypotension = tension PTX. Disconnect from ventilator, needle decompress.

⚑ Board Traps — Pneumothorax

Tension pneumothorax is a CLINICAL diagnosis — do NOT wait for CXR. Hemodynamic instability + absent breath sounds + tracheal deviation = needle decompress NOW.
Supplemental oxygen accelerates PTX reabsorption — increases nitrogen gradient. Give high-flow O₂ even if patient is not hypoxic.
Patients on positive-pressure ventilation with any pneumothorax require chest tube — observation is NOT safe (risk of tension PTX).
Recurrence of primary spontaneous PTX is ~30% after first episode → consider pleurodesis or VATS after second episode (or first if high-risk occupation: pilot, diver)
Secondary spontaneous PTX: COPD patients — lower threshold for intervention. These patients cannot compensate even for small PTX.
Needle decompression site: 2nd ICS, MCL (preferred) or 4th/5th ICS, anterior axillary line (alternative in obese)

★ Memory Trick

Tension PTX: "Trachea runs AWAY from trouble" — deviation AWAY from the PTX side "Needle decompress, then tube — never wait for the X-ray if the patient is crashing" PTX on vent: "Peak pressures up + O₂ down + BP down = tension PTX — disconnect ventilator first" Supplemental O₂ for PTX: "Nitrogen washout accelerates reabsorption — give O₂ even if not hypoxic" Recurrence after first primary PTX: "30% chance — warn the patient. Second PTX = pleurodesis conversation."

Domain 6 · Important Gap Topic

Lung Cancer ★ Gap Added

Tier 2

Topic 12 ★ Gap Added

Lung Cancer

USPSTF Screening · Cell Types · Paraneoplastic Syndromes · Superior Vena Cava Syndrome

★★ High YieldGap Topic

🔒 Full content available with bootcamp enrollment. Get access →

Why the PANCE Tests This

Lung cancer is the #1 cause of cancer death in the US. Boards test: USPSTF screening criteria, cell type characteristics (location, histology, paraneoplastic syndrome), and oncologic emergencies (SVC syndrome, hypercalcemia).

USPSTF Lung Cancer Screening — 2021 Guidelines

Annual Low-Dose CT (LDCT) Screening Criteria

Age 50–80 years (previously 55–80)
20+ pack-year smoking history (previously 30+ pack-years)
Currently smoking OR quit within the past 15 years
All 3 criteria must be met
Discontinue screening if: quit smoking >15 years ago, develop comorbidity that would limit life expectancy or willingness for curative surgery, or age >80

Cell Types — The Board-Tested Characteristics

Cell Type	Location	Classic Presentation	Paraneoplastic Syndrome	Board Key
Adenocarcinoma (#1 overall)	Peripheral, subpleural	Often asymptomatic initially. Non-smokers and women. Bronchoalveolar subtype (ground-glass opacity)	Hypertrophic osteoarthropathy (clubbing)	Most common lung cancer. Associated with EGFR, ALK, KRAS mutations → targeted therapy available.
Squamous Cell (#1 central)	Central (hilar), near carina	Hemoptysis, obstructive pneumonia, cavitating lesion, Pancoast tumor (superior sulcus)	Hypercalcemia (PTHrP secretion) — most common PNS of squamous cell	Cavitating lesion + hypercalcemia = squamous cell
Small Cell (SCLC)	Central, hilar	Rapid growth, early metastasis (brain, bone, liver, adrenal). Bulky mediastinal lymph nodes.	SIADH (#1 PNS), Cushing's (ectopic ACTH), Lambert-Eaton syndrome, SCLC + anti-Hu antibodies	Most aggressive. Nearly always metastatic at diagnosis. Responds to chemo initially. NO surgery.
Large Cell	Peripheral	Large, rapidly growing. Non-specific presentation.	Gynecomastia (β-hCG production)	Diagnosis of exclusion after other cell types ruled out

Paraneoplastic Syndromes — The Most Tested

Syndrome	Tumor Type	Mechanism	Board Key
SIADH (hyponatremia)	SCLC (#1)	Ectopic ADH production	Hyponatremia + lung mass = SCLC until proven otherwise
Hypercalcemia	Squamous cell (#1)	PTHrP (parathyroid hormone-related protein)	Cavitating mass + hypercalcemia = squamous cell
Cushing's syndrome	SCLC	Ectopic ACTH	Rapidly progressive Cushing's features + lung mass
Lambert-Eaton Myasthenic Syndrome	SCLC	Anti-VGCC antibodies (P/Q type)	Proximal muscle weakness that IMPROVES with repetition (opposite of MG)
Hypertrophic osteoarthropathy	Adenocarcinoma, squamous	Unknown	Painful periosteal new bone formation + clubbing
Pancoast tumor	Squamous cell (usually)	Apical/superior sulcus tumor invading structures	Shoulder/arm pain + Horner's syndrome (ptosis, miosis, anhidrosis) + ulnar neuropathy

Superior Vena Cava (SVC) Syndrome

Cause: Most common cause = lung cancer (especially SCLC) or lymphoma. Also mediastinal masses, thrombosis from central venous catheters.
Presentation: Facial swelling + arm edema + dilated neck/chest wall veins + dyspnea + headache. Worse with bending forward or lying down.
Diagnosis: CT chest with IV contrast — defines extent of obstruction.
Treatment: Radiation therapy (non-SCLC) or chemotherapy (SCLC) + steroids. Endovascular stenting for rapid symptom relief. NOT a surgical emergency requiring immediate decompression (unlike tension PTX).

⚑ Board Traps — Lung Cancer

USPSTF 2021 screening: age 50–80, 20+ pack-years, currently smoking or quit <15 years ago — NOT 55 or 30 pack-years (old criteria)
SCLC: NO surgery — chemotherapy is the backbone. SCLC is nearly always metastatic at diagnosis.
Lambert-Eaton: weakness IMPROVES with repetition (unlike MG where it WORSENS). Associated with SCLC.
Pancoast tumor (superior sulcus): Horner's syndrome (ptosis + miosis + anhidrosis) = cervical sympathetic chain involvement from apical tumor. Treat with concurrent chemoradiation + surgery.
Adenocarcinoma in a non-smoker — check EGFR, ALK, ROS1, KRAS mutations → may have targeted oral therapy available
SCLC + hyponatremia = SIADH from ectopic ADH — restrict fluids, consider tolvaptan for severe cases

★ Memory Trick

USPSTF Screening: "50-80, 20 pack-years, current or quit <15 years ago — all 3 required" Cell type locations: "Adenocarcinoma = Peripheral. Squamous = Central. SCLC = Central (and EVERYWHERE at diagnosis)" Paraneoplastic: "SCLC = SIADH + Cushing's + Lambert-Eaton. Squamous = HyperCalcemia." Lambert-Eaton: "Gets BETTER with exercise — OPPOSITE of myasthenia gravis (which gets WORSE)" Pancoast: "Apical tumor + Horner's syndrome (drooping eye, small pupil, dry face) + shoulder/arm pain"

Blueprint Gap Topics · Added 2025

ARDS · Obstructive Sleep Apnea · Cystic Fibrosis · Pertussis & Acute Bronchitis · Pneumoconiosis

Topics present on the 2025 NCCPA PANCE Blueprint not covered in prior modules — now fully integrated

Acute Respiratory Distress Syndrome (ARDS)

Berlin Criteria · P:F Ratio · Lung-Protective Ventilation · Prone Positioning · Neuromuscular Blockade

Why the PANCE Tests This

ARDS is the final common pathway of severe acute lung injury and appears in ICU vignettes across multiple systems. The 2025 blueprint explicitly lists it. PANCE tests Berlin criteria definitions, P:F ratio thresholds, and the lung-protective ventilation strategy.

Berlin Criteria 2012 — Three Severity Tiers

ARDS Definition — ALL 4 Must Be Present

Timing: Onset within 1 week of known clinical insult OR new/worsening respiratory symptoms
Imaging: Bilateral opacities on CXR/CT — not fully explained by effusion, collapse, or nodules
Origin: Respiratory failure NOT fully explained by cardiac failure or fluid overload (echo to exclude if uncertain)
Oxygenation: P:F ratio impaired on PEEP ≥5 cmH₂O (see tiers below)

Mild

P:F ratio 201–300 mmHg
Mortality ~27%

Moderate

P:F ratio 101–200 mmHg
Mortality ~32%

Severe

P:F ratio ≤100 mmHg
Mortality ~45%

P:F ratio = PaO₂ ÷ FiO₂. Example: PaO₂ 70, FiO₂ 0.5 → P:F = 140 (moderate ARDS). Normal P:F >400.

Common Causes — Remember "ARDS"

Pulmonary (Direct Lung Injury)

Pneumonia (most common) — bacterial, viral, aspiration
Inhalation injury (smoke, chemical)
Near-drowning · Lung contusion

Extrapulmonary (Indirect Injury)

Sepsis (most common extrapulmonary cause)
Pancreatitis · Major trauma · Burns
Massive transfusion (TRALI)
Drug overdose (heroin, aspirin)

ARDSNet Lung-Protective Ventilation — The Standard of Care

Low Tidal Volume Ventilation (ARMA Trial) — Reduces Mortality

Tidal volume: 6 mL/kg ideal body weight (not actual — prevents volutrauma)
Plateau pressure <30 cmH₂O (prevents barotrauma)
PEEP: Titrated upward to maintain oxygenation, recruit alveoli, prevent de-recruitment
SpO₂ target: 88–95% (permissive hypoxemia — hypoxia is better than barotrauma)
Permissive hypercapnia: Allow pCO₂ to rise to avoid high pressures (target pH >7.20)
⚑ High tidal volumes = worse mortality. NEVER ventilate ARDS like normal lungs.

Advanced Therapies for Severe ARDS

Prone Positioning ⭐ High-Yield

PROSEVA trial: prone ≥16h/day → 28-day mortality 16% vs 32.8% (NNT = 6)
Indication: P:F ratio <150 despite optimization
Mechanism: redistributes ventilation to dorsal lung segments, improves V/Q matching
⚑ Board trap: prone positioning is now standard of care for severe ARDS — not experimental

Other Adjuncts

Neuromuscular blockade (cisatracurium × 48h): reduces ventilator dyssynchrony — benefit for moderate-severe
Conservative fluid strategy: once resuscitated, negative fluid balance improves outcomes (FACTT trial)
ECMO: rescue therapy for severe refractory ARDS (P:F <50–80) at specialized centers
Inhaled nitric oxide / prostacyclin: improves oxygenation but no mortality benefit — bridge use only

Rapid Review Bullets

ARDS pathology: diffuse alveolar damage → capillary leak → protein-rich edema → hyaline membrane formation → fibrosis
CXR: bilateral diffuse patchy opacities ("white-out"), air bronchograms, no cardiomegaly (unlike cardiogenic pulmonary edema)
Cardiogenic vs ARDS: PCWP <18 = ARDS (not cardiogenic). Bilateral fluffy infiltrates + BNP normal + no effusions → ARDS
Steroids in ARDS: methylprednisolone for fiboproliferative phase (days 7–14) or early moderate-severe — timing controversial
No pharmacologic therapy specifically improves mortality in ARDS — lung-protective ventilation is the intervention

Obstructive Sleep Apnea (OSA)

AHI Thresholds · Epworth Scale · Polysomnography · CPAP · Cardiovascular Consequences · Obesity Hypoventilation

Recognition & Diagnosis

Classic Presentation

Obese male, loud snoring, witnessed apneas, excessive daytime sleepiness, morning headaches
Bed partner reports breathing pauses during sleep
Hypertension (especially resistant HTN) — OSA is a major secondary cause
Neck circumference >17 inches (men), >16 inches (women)

STOP-BANG Screening Tool

Snoring · Tired · Observed apneas · Pressure (HTN)
BMI >35 · Age >50 · Neck >40cm · Gender (male)
Score ≥3: high risk → polysomnography

Epworth Sleepiness Scale

Patient rates likelihood of dozing in 8 situations (0–3 each, total 0–24)
Score >10: excessive daytime sleepiness
Score >16: severe daytime sleepiness → urgent evaluation

Polysomnography — Gold Standard Diagnosis

AHI — Apnea-Hypopnea Index (events per hour)

Mild OSA: AHI 5–14 events/hour
Moderate OSA: AHI 15–29 events/hour
Severe OSA: AHI ≥30 events/hour
Home sleep testing: acceptable screening for moderate-high risk adults without comorbidities
In-lab PSG preferred: complex patients, suspected central apnea, narcolepsy evaluation

Treatment

CPAP — First-Line for Moderate-Severe OSA

Continuous positive airway pressure — pneumatic splint for airway
Titrated in lab or auto-CPAP (APAP)
Compliance threshold: ≥4h/night on ≥70% of nights
Benefits: ↓ daytime sleepiness, ↓ BP, ↓ cardiovascular events, improves quality of life
BiPAP: use if CPAP not tolerated or obesity hypoventilation coexists (hypercapnia)

Non-CPAP Options

Oral appliance therapy (mandibular advancement device): mild-moderate or CPAP-intolerant
Weight loss: most effective intervention for obese patients — AHI can normalize
Positional therapy: lateral sleep for position-dependent OSA
Hypoglossal nerve stimulator (Inspire): surgically implanted for moderate-severe, CPAP-intolerant
Uvulopalatopharyngoplasty (UPPP): surgical option — variable efficacy

Cardiovascular & Metabolic Consequences

⚑ Board-Tested Consequences of Untreated OSA

Systemic hypertension — OSA most common cause of resistant HTN
Pulmonary hypertension + cor pulmonale (chronic nocturnal hypoxia)
Atrial fibrillation — recurrence rate higher after cardioversion if OSA untreated
Type 2 DM, insulin resistance, metabolic syndrome
Increased stroke and MI risk
Polycythemia (secondary erythrocytosis from chronic hypoxia)

Obesity Hypoventilation Syndrome (OHS / Pickwickian)

OHS — Defined as Daytime Hypercapnia in Obesity

BMI ≥30 + daytime pCO₂ >45 mmHg + no other cause for hypoventilation
90% of OHS patients also have OSA
Distinguished from OSA: OHS has daytime hypercapnia (OSA alone usually doesn't)
Mechanism: obesity → ↓ chest wall compliance + blunted CO₂ response + airway obstruction
Treatment: BiPAP (not CPAP — needs pressure support for ventilation) + weight loss
⚑ Classic PANCE stem: obese patient, somnolent, pCO₂ 55 mmHg on ABG = OHS until proven otherwise

Cystic Fibrosis

CFTR Mutation · ΔF508 · Sweat Chloride · Pseudomonas Colonization · ABPA · CFTR Modulators · Pancreatic Insufficiency

Pathophysiology

Autosomal recessive mutation in the CFTR gene (chromosome 7) → defective chloride channel → thick, viscous secretions in lungs, pancreas, liver, GI tract, reproductive organs. ΔF508 (Phe508del) = most common mutation (~70% of alleles in North America).

Diagnosis

Sweat Chloride Test — Gold Standard

Pilocarpine iontophoresis (sweat test)
Positive: chloride >60 mEq/L (diagnostic)
Borderline: 30–59 mEq/L (repeat or genetic testing)
Normal: <30 mEq/L
Newborn screening: immunoreactive trypsinogen (IRT) — now standard in all 50 states
Genotyping confirms mutation; clinical criteria + sweat test is sufficient for diagnosis

Pulmonary Manifestations

Progressive Obstructive Lung Disease

Mucus plugging → recurrent infections → bronchiectasis → respiratory failure
PFTs: obstructive pattern (↓FEV1/FVC) progressing to mixed
CXR: hyperinflation, bronchiectasis, mucus plugging
Chronic productive cough, hemoptysis, digital clubbing

Infectious Organisms by Age

Children: S. aureus + H. influenzae (early)
Adolescents/Adults: Pseudomonas aeruginosa (most common, chronic colonization)
Burkholderia cepacia: multi-drug resistant, poor prognosis, transmissible between CF patients
Mucoid Pseudomonas: biofilm-forming — extremely difficult to eradicate
Treatment: inhaled tobramycin, aztreonam, oral azithromycin (anti-inflammatory)

ABPA — Allergic Bronchopulmonary Aspergillosis

Hypersensitivity to Aspergillus fumigatus colonizing CF airways
Fleeting pulmonary infiltrates + elevated IgE + eosinophilia + positive Aspergillus IgE/IgG
Treatment: oral corticosteroids + itraconazole
⚑ Classic CF complication — if CF patient has "new infiltrates + high IgE + eosinophilia" = ABPA

Extrapulmonary Manifestations

Pancreatic / GI

Pancreatic insufficiency (85%): malabsorption, steatorrhea, fat-soluble vitamin deficiency (ADEK)
CREON (pancrelipase) with every meal and snack
CF-related DM (CFRD): mixed Type 1 + Type 2 features; insulin required
Meconium ileus in newborns: first sign of CF in neonates
Distal intestinal obstruction syndrome (DIOS): constipation/obstruction in adults

Other Organ Systems

Infertility: males (bilateral absence of vas deferens — 98% infertile). Females: ↓ fertility (thick cervical mucus)
Nasal polyps + chronic sinusitis
Liver: biliary cirrhosis (10–15%)
Metabolic alkalosis: salt loss in sweat → hyponatremia + hypokalemia + hypochloremia

CFTR Modulators — Disease-Modifying Therapy

CFTR Modulators (Not Just Symptom Control)

Elexacaftor/tezacaftor/ivacaftor (Trikafta): triple combination — for ≥1 copy of ΔF508. 90% of CF patients eligible. Dramatically improves lung function, reduces exacerbations, near-normal life expectancy for many
Ivacaftor alone (Kalydeco): for specific gating mutations (G551D). "Potentiator" — opens existing CFTR channels
Mechanism: potentiators (open gate) + correctors (fix protein folding)
⚑ Board distinction: modulators treat the ROOT CAUSE (defective channel). DNase (dornase alfa) and hypertonic saline treat symptoms only

Pertussis & Acute Bronchitis

Whooping Cough Stages · Lymphocytosis · Azithromycin · Vaccine Prevention · Bronchitis — Viral, No ABx

Pertussis (Whooping Cough)

Bordetella pertussis — 3 Classic Stages

Catarrhal (1–2 weeks): URI symptoms — runny nose, low-grade fever, mild cough. Most contagious stage. Hard to distinguish from viral URI
Paroxysmal (2–6 weeks): Severe paroxysms of cough → forced inspiration = whoop. Post-tussive emesis, cyanosis. Whoop may be absent in infants (instead apnea) and adults (instead persistent cough)
Convalescent (weeks to months): Gradual resolution. Cough can persist 3 months ("100-day cough")

Diagnosis

PCR nasopharyngeal swab: most sensitive in early stages
Culture: gold standard but slow (Bordet-Gengou media)
Classic lab: marked lymphocytosis (not neutrophilia)
⚑ WBC 20,000–100,000 with lymphocyte predominance = pertussis until proven otherwise

Treatment & Prevention

Azithromycin (first-line): reduces transmission and shortens catarrhal stage; minimal effect in paroxysmal stage
TMP-SMX: alternative if macrolide intolerant
Post-exposure prophylaxis: azithromycin for close contacts
Vaccine: DTaP (children) + Tdap (booster for adolescents/adults)
Tdap in pregnancy: 27–36 weeks — transfers maternal antibodies to fetus

Acute Bronchitis

Acute Bronchitis — Viral, No Antibiotics

Acute cough ≤3 weeks with bronchial inflammation — NOT pneumonia
Etiology: viral in >90% (rhinovirus, coronavirus, influenza, parainfluenza, RSV)
Exam: no focal consolidation; mild wheezing occasionally
CXR: normal (or bilateral peribronchial thickening only)
Treatment: supportive — rest, fluids, antitussives (dextromethorphan, honey), bronchodilator if wheezing
⚑ Board trap: prescribing antibiotics for acute bronchitis = INCORRECT. Even if cough lasts 2 weeks and patient has colored sputum — still viral, no antibiotics
When to order CXR: age >65, HR >100, RR >24, T >38°C, signs of consolidation (dullness, egophony) — these suggest pneumonia

Pneumoconiosis — Occupational Lung Diseases

Silicosis · Asbestosis · Coal Workers' Pneumoconiosis · Berylliosis · Byssinosis

Core Concept

Inhalation of inorganic dusts → chronic lung fibrosis. Each dust has a characteristic CXR pattern and occupational exposure. All cause restrictive PFT pattern with ↓DLCO.

The Big Four — Occupational Exposures

Silicosis ⭐ Most Tested

Exposure: sandblasting, mining, quarrying, pottery, construction
CXR: upper lobe nodules + eggshell calcification of hilar lymph nodes
Progressive massive fibrosis (PMF): conglomerate masses (>1cm) in upper lobes
Risk of TB reactivation (silica impairs macrophage killing)
Accelerated silicosis: high-intensity exposure → faster progression

Asbestosis

Exposure: insulation workers, shipbuilders, demolition, brake mechanics
CXR: lower lobe fibrosis + pleural plaques (calcified) + "shaggy heart"
Ferruginous (asbestos) bodies in sputum/BAL — "golden rods"
Malignancies: mesothelioma (pleural) + lung adenocarcinoma
Latency: 20–40 years between exposure and disease
⚑ Pleural plaques = marker of exposure, NOT cancer itself

Coal Workers' Pneumoconiosis (CWP)

Exposure: coal miners
Simple CWP: small nodules in upper lobes (similar to silicosis but rounder, less eggshell)
No increased TB risk (unlike silicosis)

Berylliosis (Chronic Beryllium Disease)

Exposure: aerospace, nuclear weapons, electronics manufacturing
Granulomatous disease — mimics sarcoidosis on biopsy
Diagnosis: beryllium lymphocyte proliferation test (BeLPT)
Treatment: corticosteroids (like sarcoidosis)

Board Traps

⚑ High-Yield Distinctions

Upper vs lower lobe: Silicosis = upper. Asbestosis = lower. Remember: silica rises, asbestos falls (sinks to bases)
Eggshell calcification: Silicosis (and sarcoidosis) — NOT asbestosis
Mesothelioma: asbestos exposure ONLY. NOT caused by silica or coal dust
No treatment reverses pneumoconiosis — remove from exposure, treat complications, supportive care, O2
Byssinosis: cotton dust ("Monday morning chest tightness" that improves as work week progresses)

Module D · Must-Know Differentials

High-Yield Differentials & Distinguishing Features

The following differentials represent the highest-frequency diagnostic challenges in pulmonary medicine on the PANCE/PANRE. Each framework identifies the single pivotal feature that separates one diagnosis from another — the exact skill boards reward.

Tier 1

Differential D-1

Acute Dyspnea — Obstructive vs Infectious vs Vascular vs Cardiac

Asthma · COPD · PE · Pneumonia · Pneumothorax · ADHF · ARDS

★★★ Most-Tested DifferentialMultiple Lethal Traps

The Pivotal First Branch Points

Step 1 — Is it obstructive? Expiratory wheeze + reversibility = asthma. Fixed obstruction + smoking history + barrel chest = COPD. Both have wheeze — the reversibility and context separate them.
Step 2 — Is it infectious? Fever + focal consolidation + productive cough = pneumonia. Night sweats + weight loss + upper lobe + immigrant = TB. Immunocompromised + bilateral ground-glass = PCP.
Step 3 — Is it vascular? Sudden onset + pleuritic pain + risk factors + no fever = PE until ruled out. Bilateral wheeze + history of HF + JVD + orthopnea = cardiac asthma (HF).
Step 4 — Is it mechanical? Sudden pleuritic pain + absent breath sounds + tracheal deviation = pneumothorax. Hemodynamic collapse + tracheal deviation = tension PTX — treat immediately.

Distinguishing Feature Table — Acute Dyspnea

Diagnosis	Key Feature	Distinguishing Sign/Test	Cannot Miss
Asthma	Episodic wheeze, nocturnal cough, atopy, triggers	≥12% + ≥200mL FEV1 reversibility post-BD; eosinophilia	Silent chest = impending arrest, NOT improvement
COPD Exacerbation	Smoker, barrel chest, pursed-lip breathing, fixed obstruction	Low FEV1/FVC not fully reversible; hyperinflation on CXR	Rising PaCO₂ = fatigue; target SpO₂ 88–92%, not 100%
Pulmonary Embolism	Sudden onset, pleuritic, tachycardia, risk factors, no fever initially	Wells score → D-dimer or CTPA; S1Q3T3 on EKG (insensitive)	Massive PE: SBP <90 = fibrinolytics, not anticoagulation alone
Community-Acquired Pneumonia	Fever, productive cough, focal consolidation, dullness to percussion	CXR lobar consolidation; Gram stain + culture; WBC elevated	Aspiration: dependent lobes (RLL upright, RUL supine)
Tension Pneumothorax	Trauma/mechanical vent + absent breath sounds + tracheal deviation AWAY	Clinical diagnosis — hypotension + JVD + absent sounds	DO NOT get CXR — needle decompress immediately
Acute HF (Cardiac Asthma)	Orthopnea, PND, JVD, S3 gallop, bilateral crackles	BNP >400; CXR: cardiomegaly + Kerley B + bilateral effusions	BNP <100 effectively rules out HF as cause of dyspnea
ARDS	Bilateral infiltrates + hypoxia + recent trigger (sepsis, aspiration, trauma)	PaO₂/FiO₂ <300; PCWP normal (not cardiogenic)	Tidal volume 6 mL/kg IBW; plateau pressure <30 cmH₂O

⚑ Board Traps — Acute Dyspnea Differential

Cardiac asthma (HF) causes wheeze — bilateral wheeze does NOT always mean asthma or COPD. BNP, orthopnea, and JVD distinguish. Giving bronchodilators alone to cardiac asthma delays life-saving diuresis.
Normal CXR does NOT rule out PE — 30% of PEs have a normal chest X-ray. Normal CXR + dyspnea + tachycardia + risk factors = high PE suspicion.
COPD exacerbation + O₂ to 99% = hypercapnic respiratory failure in CO₂ retainers. Target 88–92%, not high-flow.
PCP in HIV looks just like ARDS — bilateral ground-glass infiltrates, hypoxia, normal or near-normal CXR early. CD4 <200 + bilateral GGO = PCP until proven otherwise.
ARDS vs cardiogenic pulmonary edema: Both have bilateral infiltrates and hypoxia. Key: PCWP normal in ARDS (<18), elevated in cardiogenic (>18). BNP low in ARDS.

★ Memory Trick

Acute dyspnea: "WHEEZES" — Wheeze (asthma/COPD/cardiac asthma), Heart failure, Embolism, Effusion, Zona (pneumothorax), Everything else, Sepsis/pneumonia BNP: "<100 rules OUT HF. >400 rules IN HF. 100–400 = clinical judgment." PE: "Normal CXR + hypoxia + tachycardia = PE until proven otherwise" Silent chest: "Quiet = Dangerous. Wheeze = air moving. Silence = NOTHING moving."

Tier 1

Differential D-2

Chronic Cough (>8 weeks) — The Big Four

Upper Airway Cough Syndrome · Asthma · GERD · ACE Inhibitor · Less Common Causes

★★★ PANCE Priority

The Four Most Common Causes of Chronic Cough

Cause	Key Feature	Diagnosis	Treatment
Upper Airway Cough Syndrome (UACS / Post-nasal drip)	Sensation of drip down throat, throat-clearing, nasal congestion. Cough worse supine.	Clinical; nasal exam shows cobblestoning	Intranasal corticosteroids + antihistamine/decongestant
Cough-Variant Asthma	Cough only — no wheeze, no dyspnea. Nocturnal. Triggers: cold, exercise, allergens.	Normal spirometry → methacholine challenge (positive = >20% FEV1 drop at ≤4 mg/mL)	ICS ± SABA; step-up per GINA
GERD-Related Cough	Postprandial, worse lying down, associated heartburn (but may be silent GERD)	Clinical; pH monitoring if unclear; empiric PPI trial	PPI + lifestyle modification; may take weeks to improve
ACE Inhibitor-Induced Cough	Dry, tickling, persistent cough in any patient on ACEi (lisinopril, enalapril, etc.)	Clinical — resolves within 1–4 weeks of stopping ACEi	Switch to ARB (same CV benefit, no cough). Do NOT rechallenge with ACEi.
Non-Asthmatic Eosinophilic Bronchitis (NAEB)	Cough, eosinophilia on sputum cytology, normal spirometry, negative methacholine	Sputum eosinophils >3%; normal airway responsiveness	ICS — excellent response

Red Flags in Chronic Cough — Order Imaging

Hemoptysis — lung cancer, TB, bronchiectasis, PE (pulmonary infarction)
Weight loss + night sweats + upper lobe infiltrate — tuberculosis until proven otherwise
Smoker age >50 + new or changed cough — lung cancer workup (LDCT if meets screening criteria)
Hoarseness + dysphagia + cough — recurrent laryngeal nerve compression (mediastinal mass, apical lung tumor)
Immunocompromised + cough + bilateral infiltrates — PCP, fungal, atypical infection

⚑ Board Traps — Chronic Cough

ACE inhibitor cough is a class effect — ALL ACEi cause it, not just one agent. Switching to a different ACEi will not fix it. Switch to ARB.
Cough-variant asthma has a normal spirometry at rest — if you only order spirometry and it is normal, you have NOT ruled out asthma. Methacholine challenge is required.
GERD-related cough may have NO heartburn — silent GERD is a common board scenario. A patient with chronic cough and no obvious reflux symptoms may still have GERD as the cause.
Empiric treatment sequence for chronic cough: Stop ACEi first (if applicable) → treat UACS → treat asthma → treat GERD. Most cases resolve with sequential empiric therapy.

Tier 1

Differential D-3

Hemoptysis — Benign to Life-Threatening

Bronchitis · TB · Lung Cancer · PE · Bronchiectasis · Massive Hemoptysis

★★★ PANCE PriorityMassive Hemoptysis Emergency

Differential by Clinical Context

Cause	Clinical Clue	Key Distinguishing Feature
Acute Bronchitis (Most Common)	Young patient, URI prodrome, pink-tinged or blood-streaked sputum, self-limited	Streaky blood mixed with mucus; CXR normal; self-resolves
Tuberculosis	Immigrant, homeless, incarcerated, HIV; night sweats, weight loss, upper lobe cavitation	Upper lobe infiltrate/cavitation; AFB smear and culture; IGRA positive
Lung Cancer	Smoker age >40; persistent hemoptysis; weight loss; new CXR mass; Pancoast features	New or enlarging mass on CXR/CT; central lesion (squamous/SCLC); PET-CT and biopsy
Pulmonary Embolism (Infarction)	Pleuritic chest pain + dyspnea + sudden onset; infarction causes true hemoptysis	Hampton's hump (wedge-shaped pleural density); Wells score + CTPA
Bronchiectasis	Chronic productive cough, recurrent pneumonias; CF, prior TB, immunodeficiency	CT: dilated bronchi ("tram-track" or "signet ring" sign); daily mucopurulent sputum
Mitral Stenosis	Rheumatic heart disease, young woman, dyspnea, opening snap on exam	Pink frothy sputum; elevated pulmonary venous pressure; echo confirms MS
Massive Hemoptysis (>300–600 mL/24h)	Any etiology; airway compromise; tachycardia; patient drowning in own blood	Airway = priority. Position bleeding side DOWN. Intubate if necessary. Bronchial artery embolization (IR) is definitive. Surgery last resort.

⚑ Board Traps — Hemoptysis

Massive hemoptysis: position the bleeding lung DOWN — prevents blood from drowning the good lung. Lateral decubitus with affected side down.
PE-related hemoptysis = pulmonary infarction (not always present). Classic: pleuritic chest pain + hemoptysis + dyspnea in a high-risk patient. Don't be reassured by a negative initial workup — raise pre-test probability.
Any persistent hemoptysis in a smoker over 40 = lung cancer until proven otherwise — order CT chest regardless of CXR findings. CXR misses 20% of lung cancers.
TB hemoptysis: Can be massive due to Rasmussen aneurysm (dilated pulmonary artery adjacent to a TB cavity). Bronchial artery embolization is the intervention of choice.

Tier 1

Differential D-4

Obstructive vs Restrictive vs Mixed — PFT Pattern Recognition

FEV1/FVC · TLC · DLCO · Clinical Correlation · DLCO Subtypes

★★★ PANCE PrioritySpirometry-Only Trap

The Master PFT Framework

Pattern	FEV1/FVC	FVC	TLC	DLCO	Clinical Examples
Obstructive	<0.70 (or below LLN)	Normal or ↓	Normal or ↑ (air trapping)	Low (emphysema) or Normal (asthma/bronchitis)	Asthma, COPD, bronchiectasis, CF
Restrictive	Normal (≥0.70)	↓	<80% predicted (required for diagnosis)	Low (ILD) or Normal (NM/chest wall)	IPF, sarcoidosis, obesity, neuromuscular
Mixed	↓	↓	↓	Variable	Combined emphysema + fibrosis, advanced sarcoidosis
Normal spirometry (possible asthma)	Normal	Normal	Normal	Normal or elevated	Cough-variant asthma — methacholine challenge needed

DLCO — The Disease Discriminator

DLCO Finding	Mechanism	Diagnoses
Low DLCO + Obstructive PFT	Alveolar wall destruction → ↓ surface area	Emphysema (COPD). Distinguishes emphysema from chronic bronchitis (normal DLCO).
Low DLCO + Restrictive PFT	Fibrosis → thickened alveolar-capillary membrane	IPF, sarcoidosis, hypersensitivity pneumonitis, CTD-ILD
Low DLCO + Normal spirometry	Vascular/capillary bed destruction without airway or parenchymal disease	Pulmonary arterial hypertension, pulmonary embolism, anemia (corrected for Hgb)
Elevated DLCO	Increased pulmonary blood volume or intrapulmonary hemorrhage	Pulmonary hemorrhage syndromes (Goodpasture, polyangiitis), left-to-right shunt, polycythemia, obesity
Normal DLCO + Obstructive PFT	Airway disease without alveolar destruction	Asthma, chronic bronchitis — alveoli intact
Normal DLCO + Low spirometry (FVC only)	Airway or chest wall/neuromuscular disease without gas exchange impairment	Neuromuscular disease, obesity (pseudo-restriction)

⚑ Board Traps — PFTs

Restriction CANNOT be diagnosed by spirometry alone. Low FVC + normal FEV1/FVC is suggestive but requires TLC <80% predicted (body plethysmography) to confirm. Low FVC also occurs from poor effort, obesity, or NM weakness.
Asthma can have a completely normal spirometry — normal FEV1/FVC at rest does not rule out asthma. Methacholine challenge is required when clinical suspicion is high.
DLCO is the key to separating emphysema from chronic bronchitis — both have obstructive spirometry. Emphysema = low DLCO. Chronic bronchitis = normal DLCO. This distinction appears on nearly every pulmonary exam.
Combined pulmonary fibrosis + emphysema (CPFE): Spirometry may look nearly normal (restriction and obstruction cancel each other) but DLCO is severely reduced. Do not be reassured by normal spirometry in a smoker with dyspnea and low DLCO.

★ Memory Trick

PFT hierarchy: "Ratio first, then FVC, then TLC, then DLCO" Emphysema vs Bronchitis: "E for Emphysema = Empty alveoli = low DLCO. B for Bronchitis = Big airways problem only = normal DLCO." Low DLCO alone (normal PFT): "Think vessels — PAH or PE" Elevated DLCO: "Hemorrhage into alveoli — blood absorbs CO"

Tier 1

Differential D-5

Pleural Effusion — Transudate vs Exudate vs Complicated

Light's Criteria · Albumin Gradient · pH Decision · RA vs Malignancy vs HF

★★★ PANCE PriorityDiuretic Light's Trap

Light's Criteria — Applied Decision Framework

Light's Criteria — Exudate if ANY ONE of Three Is Met

Pleural protein / Serum protein >0.5
Pleural LDH / Serum LDH >0.6
Pleural LDH >2/3 the upper limit of normal for serum LDH
If NONE met → Transudate. If ANY ONE met → Exudate.

Transudates vs Exudates — Clinical Differential

Category	Common Causes	Key Distinguishing Feature
Transudate	Heart failure (#1), cirrhosis, nephrotic syndrome, hypoalbuminemia	Bilateral effusions + JVD + orthopnea = HF. Bilateral + ascites + jaundice = cirrhosis.
Exudate — Infectious	Parapneumonic (simple or complicated), empyema, TB pleuritis	Fever + consolidation + effusion = parapneumonic. pH ≤7.2 = complicated → drain mandatory.
Exudate — Malignant	Lung cancer, breast, lymphoma, mesothelioma	Large unilateral effusion + weight loss + smoking. Cytology positive in ~60%.
Exudate — Inflammatory	Rheumatoid arthritis, lupus, pancreatitis, PE	RA: lowest pleural glucose of any effusion (<30 mg/dL, sometimes near 0). Lupus: ANA in fluid. Pancreatitis: high amylase.
HF on diuretics (misclassified)	HF being treated aggressively	Meets Light's exudate criteria but clinical picture = HF. Check serum-pleural albumin gradient: >1.2 g/dL = transudate despite Light's. NT-proBNP >1500 in fluid = HF confirmed.

Solitary Pulmonary Nodule — PANCE Approach

PANCE tests the decision logic, not the Fleischner size thresholds:

Low-risk nodule (<6mm, incidental, non-smoker, no risk factors): Routine follow-up, no immediate CT
Intermediate-risk (6–8mm or any size with risk factors — smoker, age >35, prior cancer): CT chest in 3–6 months
High-risk / suspicious (>8mm, spiculated, growing): PET-CT → biopsy vs surgical resection
PANCE rule: New nodule + smoker + age >35 + upper lobe = workup. New nodule + young non-smoker + round smooth margins = likely benign, follow.

🩺 PANCE Pearl: Popcorn calcification = hamartoma (benign). Central calcification = old granuloma (benign). Eccentric/no calcification + spiculated = malignant until proven otherwise.

⚑ Board Traps — Pleural Effusion

Light's criteria misclassifies ~25% of diuretic-treated HF effusions as exudates. When clinical picture = HF but Light's says exudate → check serum-pleural albumin gradient. >1.2 g/dL = transudate.
Pleural fluid pH ≤7.2 = the most critical single test for determining drainage in parapneumonic effusions. This single value determines whether antibiotics alone will work.
RA effusion has the lowest glucose — near zero in some cases. This is a classic board fact used to distinguish RA from other causes of low pleural glucose.
Bilateral effusions first get treated medically (diuretics for HF) — thoracentesis is not the initial step for bilateral effusions in the appropriate clinical context. Unilateral or atypical = tap first.
Mesothelioma = asbestos exposure + large pleural effusion + pleural thickening + NO fever. History of asbestos work is the pivotal clue.

Tier 2

Differential D-6

Solitary Pulmonary Nodule — Malignant vs Benign

Solitary Pulmonary Nodule — PANCE Approach · Risk Stratification · Calcification Patterns · Growth Rate

★★ High Yield

Calcification Pattern — The Most Tested Feature

Calcification Pattern	Implication	Common Cause
Popcorn	Benign	Hamartoma (most common benign lung tumor)
Central / Laminated / Diffuse	Benign	Granuloma (histoplasma, TB, coccidioides)
Target / Bull's-eye	Benign	Histoplasmoma
Eccentric / Stippled / Amorphous	Indeterminate — malignancy possible	Cannot exclude lung cancer — further workup needed
No calcification	Indeterminate	CT follow-up schedule based on nodule size, risk factors, and growth rate

High-Risk Features Requiring Aggressive Workup

Size >8 mm in high-risk patient — PET-CT and/or biopsy
Growth on serial CT — doubling time <400 days suggests malignancy
Spiculated margins — malignancy until proven otherwise (classic adenocarcinoma appearance)
Upper lobe location + smoker — higher malignancy risk regardless of size
Ground-glass opacity (GGO) nodule — adenocarcinoma spectrum (AIS → MIA → invasive). Slower growth but significant malignancy risk.

⚑ Board Traps — Pulmonary Nodule

Popcorn calcification = hamartoma = benign. No further workup needed. This is the one calcification pattern that definitively confirms benignity.
Spiculated nodule = malignancy until proven otherwise — irregular, stellate margins indicate local invasion into surrounding lung. This morphology overrides size criteria for workup.
A "stable" nodule is not automatically benign — stability must be demonstrated over 2 years on serial CT. Six months of stability is insufficient.
Low-risk patients (<35, never-smoker) with small smooth nodules can be observed; high-risk patients warrant more aggressive evaluation at smaller sizes.

Tier 1

Differential D-7

Pneumonia Differential — Typical vs Atypical vs Special Populations

CAP vs HAP · Typical vs Atypical · Immunocompromised · TB vs PCP vs Fungal

★★★ PANCE Priority

Typical vs Atypical Pneumonia — The Classic Distinction

Feature	Typical (Bacterial)	Atypical ("Walking")
Onset	Abrupt, with rigors	Gradual, prodrome 1–2 weeks
Cough	Productive, purulent sputum	Dry, non-productive ("walking pneumonia")
CXR	Lobar or segmental consolidation	Bilateral diffuse, patchy, interstitial infiltrates
Organisms	S. pneumoniae (#1), H. influenzae, Moraxella, Klebsiella	Mycoplasma (#1 in young adults), Chlamydophila, Legionella
Treatment	Beta-lactam (amoxicillin outpatient; ceftriaxone inpatient)	Macrolide (azithromycin) or doxycycline or fluoroquinolone
Lab clue	High WBC, elevated procalcitonin, positive Gram stain	Cold agglutinins (Mycoplasma), Legionella urine antigen, Chlamydia serology

Special Populations — The Board Favorites

Population	Pathogen to Know	Key Clinical Clue
HIV+ CD4 <200	Pneumocystis jirovecii (PCP)	Bilateral ground-glass infiltrates + dry cough + subacute onset + LDH elevated. Normal or near-normal CXR early. TMP-SMX first-line; add prednisone if PaO₂ <70.
Alcoholic / Poor dentition	Aspiration pneumonia — anaerobes (Bacteroides, Peptostreptococcus)	RLL (upright) or RUL posterior (recumbent aspiration); putrid sputum; lung abscess
COPD / smoker	H. influenzae, Moraxella catarrhalis, S. pneumoniae	Exacerbation + infiltrate; prior antibiotic exposure increases resistant organisms
Ohio/Mississippi Valley	Histoplasma capsulatum	Bird/bat droppings exposure; mediastinal lymphadenopathy; calcified granulomas
Southwest US (desert)	Coccidioides immitis	Valley fever; arthralgias, erythema nodosum; "Valley fever" = Coccidioidomycosis
Pacific Northwest / Great Lakes	Blastomyces dermatitidis	Skin lesions + lung disease; verrucous skin ulcers
Immunocompromised (neutropenia)	Aspergillus fumigatus	Halo sign on CT (ground-glass surrounding nodule); galactomannan antigen; treat with voriconazole

Legionella — The High-Yield Atypical

Classic patient: Older male, smoker, immunosuppressed, recent hotel/hospital exposure, contaminated water systems
Classic features: Severe CAP + hyponatremia + diarrhea + elevated liver enzymes + confusion (extrapulmonary features)
Diagnosis: Legionella urinary antigen (fast, detects serogroup 1 = 80% of cases). Sputum culture on BCYE agar.
Treatment: Fluoroquinolone (levofloxacin) or azithromycin — beta-lactams do NOT work (Legionella is intracellular)

⚑ Board Traps — Pneumonia

Metronidazole is NOT routinely added to CAP regimens — adding anaerobic coverage to community-acquired pneumonia increases mortality (IDSA 2019 guidelines). It is used for aspiration pneumonia/abscess, not standard CAP.
Legionella is NOT covered by beta-lactams — it is an intracellular pathogen. Macrolides or fluoroquinolones are required. A patient with severe CAP not responding to ceftriaxone alone should prompt consideration of Legionella.
PCP: normal or near-normal CXR early — bilateral GGO on CT is the classic finding. LDH is elevated (sensitive but not specific). Treat empirically in HIV+ with CD4 <200 and compatible presentation while awaiting bronchoscopy.
Aspiration pneumonia vs aspiration pneumonitis: Pneumonitis = chemical injury from acid, resolves without antibiotics in 24–48h. Pneumonia = bacterial superinfection, requires antibiotics. Location matters: right lower lobe (upright) or right upper lobe posterior segment (recumbent).

Module E · Comprehensive Board Pearls

Board Pearls — Organized by Domain

These pearls represent the exact clinical decision points most frequently tested on PANCE/PANRE pulmonary questions. Each pearl targets a specific mechanism the exam uses to separate passing from failing candidates.

Tier 1

Board Pearls — Obstructive Lung Disease

Asthma & COPD — High-Yield Decision Points

★★★ Highest Yield

SABA-only therapy is obsolete (GINA 2024). All asthma patients need ICS-containing therapy at every step. As-needed low-dose ICS-formoterol for mild asthma reduces exacerbations by ≥60% vs SABA alone.
LABA monotherapy is contraindicated in asthma (increases asthma-related death) but is appropriate in COPD. This distinction is tested every exam cycle.
Silent chest in asthma = impending respiratory failure, NOT improvement. No air movement = no wheeze. Normal or rising PaCO₂ in severe asthma = respiratory muscle fatigue = prepare for intubation.
IV magnesium sulfate 2g over 20 minutes is for severe asthma exacerbation not responding to bronchodilators. It relaxes bronchial smooth muscle via calcium antagonism.
Do NOT sedate the agitated asthmatic. Agitation = hypoxia, not anxiety. Sedation removes respiratory drive and precipitates arrest.
COPD O₂ target: SpO₂ 88–92%. High-flow O₂ suppresses hypoxic drive in CO₂ retainers → hypercapnic respiratory failure. LTOT target is not 95%+.
LTOT indication: PaO₂ ≤55 OR SpO₂ ≤88% at rest. Or PaO₂ 55–60 if pulmonary HTN, cor pulmonale, or polycythemia. SpO₂ 89–93% without additional risk factors does NOT meet criteria (LOTT trial).
COPD Gold Group B: dual bronchodilation (LAMA + LABA) is preferred first-line. ICS is not routinely added unless eosinophilia ≥300 or ≥2 exacerbations per year.
Roflumilast (PDE4 inhibitor): Add-on for GOLD Group E (severe, frequent exacerbations) with chronic bronchitis phenotype. Contraindicated in underweight patients (causes significant weight loss).
Alpha-1 antitrypsin deficiency: Young non-smoker or minimal smoker with early-onset panlobular (basilar) emphysema + liver disease. Serum A1AT level + phenotype. Augmentation therapy if indicated.

Tier 1

Board Pearls — Pulmonary Infections

CAP · TB · PCP · Atypical Organisms · Drug Toxicity

★★★ Highest Yield

Inpatient CAP standard regimen: ceftriaxone + azithromycin. Fluoroquinolone monotherapy is an alternative, not first-line. Metronidazole is NOT added to CAP (increases mortality).
BCG vaccination causes false-positive TST but NOT IGRA. Always use IGRA in BCG-vaccinated patients from endemic countries. HIV+ lowers TST threshold to ≥5mm.
Active TB vs LTBI distinction: Active = symptoms + CXR abnormality + positive AFB smear/culture. LTBI = positive test + no symptoms + normal CXR. RIPE therapy for active; INH × 9 months (or 3HP) for LTBI.
RIPE drug toxicity — memorize all four: Rifampin = orange body fluids (benign) + CYP450 inducer (lowers many drug levels including OCP, warfarin). Isoniazid = peripheral neuropathy (give B6/pyridoxine) + hepatotoxicity. Pyrazinamide = hyperuricemia (gout). Ethambutol = optic neuritis (monitor color vision monthly).
PCP prophylaxis: TMP-SMX when CD4 <200. Treat active PCP with TMP-SMX IV. Add prednisone if PaO₂ <70 mmHg or A-a gradient >35 (reduces inflammation, improves survival).
Legionella: beta-lactams do NOT work. Intracellular pathogen requires macrolide or fluoroquinolone. Urine antigen is the fastest diagnostic test. Classic clue: CAP + hyponatremia + diarrhea.
Geographic fungi — memorize the map: Ohio/Mississippi Valley = Histoplasma. Southwest desert = Coccidioides ("Valley Fever"). Pacific Northwest/Great Lakes = Blastomyces. Immunocompromised anywhere = Aspergillus (halo sign on CT → voriconazole).
CURB-65 score ≥2 = hospitalization recommended for CAP. CURB-65: Confusion, Urea >7, RR ≥30, BP <90/60, age ≥65. Score 0–1 = outpatient; 2 = inpatient; 3–5 = consider ICU.

Tier 1

Board Pearls — ILD, Sarcoidosis & Pulmonary Hypertension

IPF · Sarcoid · PAH · WHO Groups · Cor Pulmonale

★★★ Highest Yield

IPF treatment: antifibrotics (nintedanib or pirfenidone) slow FVC decline but do not reverse fibrosis. Corticosteroids do NOT help IPF and may worsen prognosis. The PANTHER trial showed triple immunosuppression (AZA + NAC + prednisone) increased mortality — abandoned.
UIP pattern on HRCT = IPF diagnosis without biopsy in the right clinical context (older male smoker, Velcro crackles, clubbing). Honeycombing + traction bronchiectasis in subpleural basal distribution = UIP.
Löfgren syndrome = clinical diagnosis of sarcoidosis, no biopsy required. Triad: bilateral hilar lymphadenopathy + erythema nodosum + ankle periarthritis. Excellent prognosis; 85–90% spontaneous resolution.
Serum ACE is NOT diagnostic for sarcoidosis — it is neither sensitive nor specific enough. Tissue biopsy showing non-caseating granulomas is required (unless Löfgren syndrome).
Sarcoidosis cardiac involvement: complete heart block or VT in a young patient — always consider sarcoid when cardiac conduction disease occurs in a young patient with bilateral hilar adenopathy.
WHO Group 3 (lung disease) pulmonary hypertension: PAH-specific drugs are NOT indicated — they worsen V/Q mismatch. Treat underlying lung disease + LTOT. PAH-specific drugs are for WHO Group 1 only (after right heart catheterization).
Right heart catheterization is required to definitively diagnose PAH — mean PAP >20 mmHg at rest + PCWP ≤15. Echo estimates RVSP but cannot replace RHC for diagnosis or drug decisions.
Cor pulmonale (RV failure from lung disease): JVD + peripheral edema + RV heave + P2 loud + right-sided S3. Treat with O₂ (most important), diuretics cautiously, treat underlying lung disease. NOT with vasodilators (worsen V/Q mismatch).

Tier 1

Board Pearls — PE, Pleural Disease & Pneumothorax

Wells Criteria · Fibrinolytics · Light's Criteria · pH Rule · Tension PTX

★★★ Highest YieldMultiple Emergency Traps

Wells ≤4 = PE unlikely → D-dimer first. Wells >4 = PE likely → CTPA directly. Negative D-dimer with low pre-test probability excludes PE. D-dimer is a rule-out test only.
PERC rule: if ALL 8 criteria met in a patient with <15% pre-test probability → no further PE workup. PERC is not applied to intermediate or high pre-test probability patients.
Massive PE (SBP <90): systemic fibrinolytics (alteplase 100mg IV over 2 hours) if no contraindications. Anticoagulation alone is insufficient. IVC filter does NOT treat the hemodynamic crisis.
DOACs are first-line for PE treatment with two exceptions: antiphospholipid syndrome (warfarin only — TRAPS trial) and mechanical heart valves (warfarin only).
Apixaban and rivaroxaban need NO parenteral bridge. Dabigatran and edoxaban require 5–10 days of LMWH before starting. This distinction is tested.
Duration of anticoagulation: Provoked PE (surgery, immobility) = 3 months. Unprovoked = minimum 3 months, discuss extended therapy. Cancer-associated = LMWH or DOAC (rivaroxaban or apixaban) indefinitely while cancer active.
Light's criteria misclassifies ~25% of diuretic-treated HF effusions as exudates. Corrective test: serum-pleural albumin gradient >1.2 g/dL = transudate. NT-proBNP >1500 in pleural fluid = HF confirmed.
Pleural fluid pH ≤7.2 is the single most important decision point for parapneumonic drainage. This value mandates chest tube placement. Antibiotics alone fail at this pH.
RA pleural effusion has the lowest glucose (<30 mg/dL, sometimes near 0). Classic board fact separating RA from other low-glucose exudates.
Tension pneumothorax = clinical diagnosis — DO NOT get CXR. Absent breath sounds + tracheal deviation AWAY from affected side + hemodynamic collapse = needle decompression at 2nd ICS, MCL immediately. Then chest tube. Seconds matter.
Supplemental O₂ accelerates PTX reabsorption by nitrogen washout — give high-flow O₂ even in normoxic patients with pneumothorax.
Any patient on positive-pressure ventilation with a pneumothorax requires chest tube. Observation is NOT safe — risk of rapid tension PTX with every breath.

Tier 1

Board Pearls — Lung Cancer & Screening

USPSTF Criteria · Cell Types · Paraneoplastic Syndromes · SVC Syndrome

★★★ Highest Yield

USPSTF 2021 lung cancer screening (LDCT): age 50–80, ≥20 pack-years, currently smoking or quit within 15 years. All three must be met. Stop at age 80 or if quit >15 years ago.
Adenocarcinoma (#1 most common overall): Peripheral, non-smokers, women, EGFR/ALK/KRAS mutations → targeted therapy. Associated with hypertrophic osteoarthropathy (clubbing). Ground-glass opacity on CT.
Squamous cell (#1 central): Hilar/central, cavitates, smoker. Paraneoplastic = PTHrP-mediated hypercalcemia (PTH suppressed). Pancoast tumor (superior sulcus) = Horner syndrome + brachial plexopathy + shoulder/arm pain.
SCLC paraneoplastics — memorize all: SIADH (hyponatremia, most common), ectopic ACTH (Cushing's), Lambert-Eaton myasthenic syndrome (weakness improves with repetition — OPPOSITE of MG), anti-Hu antibodies (encephalitis). SCLC = chemo only, no surgery.
Lambert-Eaton vs Myasthenia Gravis: Lambert-Eaton = proximal weakness that IMPROVES with repetition (calcium channel antibodies), VGCC antibodies. MG = weakness that WORSENS with repetition (AChR antibodies). SCLC = Lambert-Eaton. Thymoma = MG.
SVC syndrome: Facial swelling + arm swelling + headache + dilated neck/chest veins. SCLC is the #1 cause. Urgent radiation ± stenting. Elevate head of bed. Steroids for symptom relief.
Horner syndrome from Pancoast tumor: Ptosis + miosis + anhidrosis (ipsilateral). Apical lung cancer invading the superior cervical sympathetic chain. Always order chest CT with apical views when Horner is found.
Large cell carcinoma is a diagnosis of exclusion — when no glandular (adeno), squamous, or small cell differentiation is identified. Associated with gynecomastia (β-hCG). Peripheral, poorly differentiated, aggressive.

Tier 1

Board Pearls — Pulmonary Pharmacology

Contraindications · Drug Interactions · Monitoring · Key Distinctions

★★★ Highest YieldDrug Trap Targets

LABA contraindication in asthma: LABA monotherapy without ICS is absolutely contraindicated. Always combine with ICS. In COPD, LABA monotherapy is acceptable.
ICS side effects: Oral candidiasis (prevent by rinsing mouth after use) and dysphonia. NOT systemic immunosuppression at standard doses. High-dose ICS can suppress HPA axis.
Theophylline (methylxanthine): Narrow therapeutic index. Toxicity: nausea, tremor, tachycardia, seizures. Level 10–15 μg/mL therapeutic; >20 = toxic. Many drug interactions (macrolides, fluoroquinolones increase levels). Rarely used now.
Rifampin is a potent CYP450 inducer — reduces levels of warfarin, oral contraceptives, methadone, many HIV antiretrovirals, azole antifungals. Counsel patients on alternative contraception during TB treatment.
Isoniazid requires pyridoxine (B6) supplementation — prevents peripheral neuropathy (especially in elderly, malnourished, diabetics, pregnant women, alcoholics). Standard dose: 25–50 mg/day.
Sildenafil/tadalafil (PDE5 inhibitors) for PAH: Cannot be combined with nitrates (severe hypotension). Used for WHO Group 1 PAH. Not for Group 3 (lung disease) — worsens V/Q mismatch.
Macrolides for COPD (azithromycin 250mg daily): Reduces exacerbation frequency in GOLD Group E patients. Risk: QT prolongation (check EKG baseline), hearing loss, Mycobacterium avium complex (MAC) resistance. Not for current smokers (higher risk of respiratory events).
Systemic corticosteroids in COPD exacerbation: Prednisone 40mg × 5 days. No benefit beyond 5 days (REDUCE trial). No taper needed for short courses. Reduces treatment failure and hospital stay.
TMP-SMX in PCP: dose is weight-based (15–20 mg/kg/day TMP component). Prophylaxis dose: one double-strength tablet daily. Adverse effects: rash (Stevens-Johnson in HIV), hyperkalemia, nephrotoxicity.

Fast Review

10 Rapid-Fire Pulmonary Clinical Pearls

1
SABA-only asthma treatment is obsolete — all patients need ICS-containing therapy (GINA 2024). As-needed low-dose ICS-formoterol for mild asthma reduces exacerbations by ≥60% vs SABA alone. LABA monotherapy without ICS is absolutely contraindicated in asthma.
2
Silent chest + normal/rising PaCO₂ in asthma = impending respiratory failure, not improvement. Severe asthmatics should be hyperventilating (low PaCO₂). A "normal" CO₂ in a severe exacerbation is catastrophically abnormal.
3
LTOT target SpO₂ in COPD is 88–92%. Too little = tissue hypoxia. Too much = suppresses hypoxic drive in CO₂ retainers → hypercapnia. LTOT does NOT benefit moderate resting hypoxemia (SpO₂ 89–93%) per LOTT trial.
4
Restrictive lung disease CANNOT be diagnosed by spirometry alone. Low FVC with normal FEV1/FVC = suggestive but not diagnostic. TLC <80% predicted (measured by body plethysmography) is required to confirm true restriction.
5
BCG vaccination causes false-positive TST but NOT IGRA. Use IGRA in BCG-vaccinated immigrants. HIV+ lowers TST threshold to ≥5mm. INH toxicity: peripheral neuropathy (give pyridoxine/B6) + hepatotoxicity. Ethambutol = optic neuritis.
6
Tension pneumothorax is a clinical diagnosis — do NOT wait for CXR. Absent breath sounds + tracheal deviation AWAY from affected side + hemodynamic collapse = needle decompress immediately (2nd ICS, MCL). Seconds matter.
7
DOACs are first-line for PE treatment — with two exceptions. Antiphospholipid syndrome: warfarin only (DOACs inferior per TRAPS trial). Mechanical heart valves: warfarin only. Apixaban and rivaroxaban require NO parenteral bridge. Dabigatran and edoxaban require 5–10 days LMWH first.
8
Pleural fluid pH ≤7.2 = complicated parapneumonic effusion — chest tube is mandatory. pH is the single most important test. Antibiotics alone will NOT resolve it. If empyema (frank pus) — always drain. RA effusion = lowest pleural glucose (<30, sometimes near 0).
9
SCLC paraneoplastic syndromes: SIADH (hyponatremia), ectopic ACTH (Cushing's), Lambert-Eaton (weakness improves with repetition — opposite of MG). Squamous cell = PTHrP-mediated hypercalcemia. SCLC: no surgery — chemotherapy only. Nearly always metastatic at diagnosis.
10
Löfgren syndrome = bilateral hilar adenopathy + erythema nodosum + ankle arthritis (± fever). Clinical diagnosis — no biopsy required. Excellent prognosis (85–90% spontaneous resolution). Non-caseating granulomas = sarcoid. Caseating = TB.

Clinical Emergency List

10 "Don't Miss" Pulmonary Emergencies

1. Tension Pneumothorax

Clinical diagnosis — never wait for CXR. Absent breath sounds + tracheal deviation AWAY from affected side + hemodynamic collapse. Needle decompress immediately (14–16G, 2nd ICS, MCL), then chest tube. Seconds count — this kills in minutes. On mechanical ventilation: suddenly ↑ peak pressures + ↓ O₂ + ↓ BP = tension PTX.

2. Massive Pulmonary Embolism

SBP <90 + confirmed PE on CTPA or echo. Systemic thrombolysis (alteplase 100mg IV over 2h) if no contraindications. Anticoagulation alone is insufficient. Surgical embolectomy if lytics fail or are contraindicated. Mortality without treatment approaches 60%. Start anticoagulation simultaneously with thrombolytics.

3. Status Asthmaticus (Life-Threatening Exacerbation)

Silent chest + rising PaCO₂ + SpO₂ <90% despite bronchodilators. IV magnesium 2g + continuous nebulized albuterol + ipratropium + IV steroids. Prepare for intubation. Permit permissive hypercapnia on vent. Do NOT sedate the agitated patient — agitation = hypoxia. Heliox for refractory bronchospasm.

4. COPD Exacerbation with Hypercapnic Respiratory Failure

PH <7.35, PaCO₂ rising, increasing work of breathing. BiPAP is first-line — NOT intubation. BiPAP reduces intubation rate, mortality, and ICU stay. Failure of BiPAP or contraindication (coma, aspiration risk, hemodynamic instability) → intubate. Set vent to prevent auto-PEEP (prolonged expiratory time, low RR).

5. Massive Hemoptysis

Coughing >500–600 mL blood/24h or any hemoptysis causing hemodynamic instability. Most common causes: TB, bronchiectasis, lung cancer, aspergilloma. Protect the airway first — position affected side DOWN. Bronchoscopic localization + endobronchial tamponade → bronchial artery embolization (IR) → surgery if all else fails. ICU admission.

6. Acute Respiratory Distress Syndrome (ARDS)

Bilateral infiltrates + P/F ratio <300 + not from HF + onset within 7 days of insult. Lung-protective ventilation: Tidal volume 6 mL/kg IBW, plateau pressure <30 cmH₂O, PEEP titration. Prone positioning for P/F <150. Neuromuscular blockade for severe ARDS. Avoid fluid overload. No proven pharmacotherapy.

7. Empyema

Frank pus in pleural space — always drain, no exceptions. Antibiotics alone will not resolve empyema. Chest tube insertion mandatory. If loculated: intrapleural fibrinolytics (tPA + DNase) or VATS decortication. pH <7.2 in parapneumonic effusion = complicated → drain before frank empyema develops. Do NOT procrastinate — undrainable loculation develops rapidly.

8. Epiglottitis (Upper Airway Emergency)

Adult: Hib, Streptococcus. "Tripod position" + drooling + muffled voice + severe odynophagia + "thumbprint sign" on lateral CXR. DO NOT do direct laryngoscopy without airway control ready. Controlled intubation in OR with ENT/anesthesia present. IV antibiotics (ceftriaxone). Racemic epinephrine while preparing airway.

9. Superior Vena Cava (SVC) Syndrome

Facial plethora + bilateral arm edema + dilated neck/chest wall veins + dyspnea. Most common cause = lung cancer (especially SCLC) or lymphoma. CT chest with IV contrast confirms. Urgent radiation (non-SCLC) or chemo (SCLC) + steroids. Endovascular stenting for rapid symptom relief. NOT an immediate surgical emergency, but biopsy before treatment if possible.

10. Miliary Tuberculosis

Hematogenous dissemination — bilateral "millet seed" nodules on CXR (1–2mm). Fever + night sweats + weight loss + multiorgan failure. Can cause TB meningitis (LP for AFB), bone/joint TB, hepatic involvement, Addison's disease (adrenal TB). Initiate RIPE therapy immediately — do not await culture results if clinical suspicion high. Consider steroids if concurrent TB meningitis.

Chapter Summary

Top 20 Pulmonary Board Traps

From your source material + confirmed. These are the PANCE-winning distinctions.

20 Traps · All Domains

Asthma — GINA 2024

SABA-only treatment is NO LONGER recommended for asthma at any severity. All patients need ICS-containing therapy. As-needed ICS-formoterol is preferred for mild asthma.

Asthma — LABA Safety

LABA monotherapy is CONTRAINDICATED in asthma (increases asthma-related death). Must always combine with ICS. LABA alone is acceptable in COPD — not in asthma.

Asthma — Silent Chest

Silent chest in acute asthma = impending respiratory failure, NOT improvement. No wheezing = no air movement. More dangerous than audible wheezing.

Asthma — PaCO₂ Trap

Normal or rising PaCO₂ in severe asthma = respiratory muscle fatigue and impending arrest. Patients should be hyperventilating (low CO₂). "Normal" CO₂ = catastrophically abnormal.

Asthma vs COPD — Spirometry

Asthma = reversible obstruction (≥12% + ≥200mL FEV1 improvement post-BD). COPD = irreversible. This is the single most important spirometric distinction on boards.

PFTs — Restriction Rule

Restrictive disease CANNOT be diagnosed by spirometry alone. Low FVC with normal FEV1/FVC = suggestive only. TLC <80% predicted (body plethysmography) is required to confirm.

PFTs — DLCO

DLCO differentiates emphysema (low) from chronic bronchitis (normal) and asthma (normal/high). Both emphysema and bronchitis are obstructive — DLCO is the key differentiator.

COPD — ICS Rule

ICS monotherapy is NEVER appropriate in COPD. Always combine with a long-acting bronchodilator. ICS in COPD increases pneumonia risk — use only when clearly indicated (eos ≥300, frequent exacerbations).

COPD — Eosinophils Guide ICS

Blood eosinophil count guides ICS use in COPD: ≥300 cells/μL = likely benefit. <100 = unlikely benefit. 100–300 = consider based on exacerbation frequency.

COPD — LTOT

LTOT benefits severe resting hypoxemia (SpO₂ ≤88%) only — NOT moderate hypoxemia. LOTT trial: no benefit for SpO₂ 89–93% or exercise-only desaturation. O₂ target 88–92%.

COPD — O₂ Target

Target SpO₂ 88–92% in COPD — excessive O₂ suppresses hypoxic drive in CO₂ retainers and worsens hypercapnia. Do NOT target 95–100%.

COPD — BiPAP

NIV (BiPAP) is first-line for COPD exacerbation with respiratory failure — reduces intubation, mortality, and ICU stay. Reserve intubation for BiPAP failure or contraindication.

CAP — Fluoroquinolones

Fluoroquinolones are NOT first-line for CAP. Reserve for β-lactam/macrolide intolerance. Risks: C. diff, tendon rupture, QT prolongation, resistance. β-lactam + macrolide is preferred inpatient.

CAP — Antibiotic Duration

3-day antibiotic course is sufficient for hospitalized CAP if stability criteria met by day 3 (afebrile, HR <100, RR <24, SBP ≥90, SpO₂ ≥90%, able to eat). Longer courses are NOT superior.

CAP — Aspiration

Do NOT add anti-anaerobic coverage (metronidazole, clindamycin) for aspiration pneumonia — associated with 5–6% higher mortality. Standard CAP antibiotics are adequate per 2019 ATS/IDSA guidelines.

PE — D-Dimer Rule

D-dimer is a RULE-OUT test only for PE — do NOT order in high-probability patients (Wells >4, go straight to CTPA). A positive D-dimer does NOT diagnose PE. It is highly sensitive but not specific.

PE — DOACs First-Line

DOACs are first-line for PE treatment — warfarin is no longer preferred. Exceptions: antiphospholipid syndrome (warfarin only — TRAPS trial) and mechanical heart valves (warfarin only).

PE — Thrombolysis Threshold

Systemic thrombolysis for MASSIVE PE only (SBP <90 mmHg). NOT for submassive PE unless hemodynamic deterioration occurs despite anticoagulation.

Pleural — pH Rule

Pleural fluid pH ≤7.2 = complicated parapneumonic effusion requiring chest tube drainage. The most critical test for determining need for drainage. Antibiotics alone will NOT resolve it.

PTX — Clinical Diagnosis

Tension pneumothorax = clinical diagnosis — immediate needle decompression, do NOT wait for CXR. Absent breath sounds + tracheal deviation away from PTX + hemodynamic collapse = needle decompress now.

Quick-Scan Reference — Numbers That Win Points

ASTHMA REVERSIBILITY

≥12% AND ≥200mL FEV1↑ post-BD

COPD O₂ TARGET

SpO₂ 88–92%
LTOT if SpO₂ ≤88%

IV Mg ASTHMA

2g IV over 20 min
(severe, refractory)

PLEURAL DRAINAGE

pH ≤7.2 → chest tube
Empyema → always drain

PE THROMBOLYSIS

Alteplase 100mg / 2h
Massive only (SBP <90)

TB RIPE DURATION

2 months RIPE
+ 4 months RI = 6 months

LUNG CA SCREENING

Age 50–80, ≥20 pack-yrs
Current or quit <15 yrs

TST THRESHOLDS

≥5mm: HIV/contacts
≥10mm: high-risk groups
≥15mm: anyone

⬡ Closing Statement

"Pulmonary on the PANCE rewards the student who has internalized the exceptions. The silent chest that looks calm. The CO₂ that looks normal. The SABA-only inhaler that looks like enough. The tension PTX that you should never wait to image. These are the moments that define board performance — and clinical practice. Master the traps, and the right answer becomes obvious."

— Rajiv Choudhary, MD, MPH

Pulmonary MedicineBootcamp Syllabus

You've seen the preview.Unlock all 17 Pulmonary topics.

Pulmonary Medicine
Bootcamp Syllabus

You've seen the preview.
Unlock all 17 Pulmonary topics.